aspirin has been researched along with Arteriosclerosis in 388 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 9.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| "Our results indicate that the combined regimen of clopidogrel and aspirin has beneficial effects on regulating platelet activation and inflammatory processes in acute atherosclerotic ischemic stroke." | 9.10 | Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. ( Bae, HR; Cha, JK; Cheon, SM; Jeong, MH; Lee, KM; Lim, YJ; Park, KW, 2002) |
| "Patients with atrial fibrillation and with documented aortic plaque who were assigned to adjusted-dose warfarin therapy (international normalized ratio 2." | 9.09 | Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography. ( Asinger, R; Blackshear, JL; Fenster, P; Halperin, J; Pearce, LA; Pennock, G; Strauss, R; Zabalgoitia, M, 1999) |
| "In order to evaluate the effect of triflusal (2-acetyloxy-4-trifluoromethyl benzoic acid), an orally active antiplatelet agent, on arteriosclerosis progression, a pilot, parallel, double-dummy, double-blind clinical trial vs acetylsalicylic acid (ASA) was carried out in patients with subclinical atherosclerotic lesions." | 9.09 | Effects of triflusal on arteriosclerosis progression assessed with high-resolution arterial ultrasound. ( Ambrosoli, L; Belcaro, G; Cesarone, MR; DeSanctis, MT; Fugazza, L; Girardello, R; Incandela, L; Laurora, G; Peracino, L; Poli, A, 1999) |
| "To define the effect of aspirin use on stroke and other major vascular events when given for primary prevention to persons without clinically recognized vascular disease." | 8.80 | Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. ( Benavente, O; Halperin, JL; Hart, RG; Kronmal, RA; Man-Son-Hing, M; McBride, R, 2000) |
| " In patients with arterial or venous thrombosis, there is a high rate of recurrence during the two first years except if high-dose warfarin was used (i." | 8.80 | [Aspirin and antiphospholipid syndrome]. ( Blétry, O; Hachulla, E; Hatron, PY; Piette, AM, 2000) |
| "To explore the interactive effect of low-dosage aspirin (ASA) combined with perindopril (PER), on prostacyclin (PGI2), thromboxone A2 (TXA2), and norepinephrine (NE) in the blood of arteriosclerosis rabbit models and the cardiac function." | 7.72 | [Effect of aspirin combined with perindopril on prostacyclin, thromboxone A2, and norepinephrine in the blood of arteriosclerosis rabbit models and the cardiac function]. ( Li, J; Liu, LH; Zhuang, HP, 2003) |
| "Thromboxane A2 (TXA2) biosynthesis was studied in healthy subjects, patients with chronic cerebral infarction, patients under chronic aspirin treatment and patients with atrial fibrillation." | 7.68 | Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction. ( Hayashi, Y; Nakahama, H; Nakanishi, T; Shimizu, S; Sugita, M; Takiguchi, A; Uyama, O; Yamamoto, S, 1992) |
| " This explains the different dosage requirements of aspirin as an antithrombotic (COX-1) and an anti-inflammatory drug (COX-2), respectively." | 6.40 | Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. ( Schrör, K, 1997) |
| "However, systemic study of thrombus formation in vein grafts is still lacking, and few effective techniques are available to prevent this event." | 5.32 | Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection. ( Hu, Y; Mayr, U; Thompson, WD; Torsney, E; Xu, Q; Zou, Y, 2004) |
| "Ciprofibrate was most effective in lowering the levels of triacylglycerids (-41%) and VLDL-cholesterol (-34%), but effectively lowered also the values of total cholesterol and LDL-cholesterol." | 5.30 | [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia]. ( Cibulova, L; Fedelesova, V; Gajdos, M; Huttova, D; Krivosikova, Z; Mongiellova, V; Polak, F, 1999) |
| "This large-scale trial of patients at high risk for atherothrombotic events will allow determination of the value of a strategy of adding clopidogrel to the current standard of care, including low-dose aspirin, for a wide spectrum of patients with atherothrombosis." | 5.11 | Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. ( Bhatt, DL; Topol, EJ, 2004) |
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 5.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| "Our results indicate that the combined regimen of clopidogrel and aspirin has beneficial effects on regulating platelet activation and inflammatory processes in acute atherosclerotic ischemic stroke." | 5.10 | Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. ( Bae, HR; Cha, JK; Cheon, SM; Jeong, MH; Lee, KM; Lim, YJ; Park, KW, 2002) |
| "In order to evaluate the effect of triflusal (2-acetyloxy-4-trifluoromethyl benzoic acid), an orally active antiplatelet agent, on arteriosclerosis progression, a pilot, parallel, double-dummy, double-blind clinical trial vs acetylsalicylic acid (ASA) was carried out in patients with subclinical atherosclerotic lesions." | 5.09 | Effects of triflusal on arteriosclerosis progression assessed with high-resolution arterial ultrasound. ( Ambrosoli, L; Belcaro, G; Cesarone, MR; DeSanctis, MT; Fugazza, L; Girardello, R; Incandela, L; Laurora, G; Peracino, L; Poli, A, 1999) |
| "Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8." | 5.09 | Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999) |
| "Patients with atrial fibrillation and with documented aortic plaque who were assigned to adjusted-dose warfarin therapy (international normalized ratio 2." | 5.09 | Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography. ( Asinger, R; Blackshear, JL; Fenster, P; Halperin, J; Pearce, LA; Pennock, G; Strauss, R; Zabalgoitia, M, 1999) |
| "Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| "The use of low doses of aspirin on a daily basis has increased greatly in the past 20 years, based on observations that it can significantly reduce the risk of heart attacks and strokes." | 4.81 | Potential cardioprotective actions of no-releasing aspirin. ( Fiorucci, S; Ignarro, LJ; Wallace, JL, 2002) |
| " In primary prevention, the benefit of aspirin has been established only for patients with non-valvular atrial fibrillation and a low risk of cardioembolism, or as an alternative choice of warfarin, and in subjects at high risk of atherosclerosis." | 4.80 | [Prevention of cerebral ischemia: anti-platelet agents]. ( Leys, D, 1999) |
| "To define the effect of aspirin use on stroke and other major vascular events when given for primary prevention to persons without clinically recognized vascular disease." | 4.80 | Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. ( Benavente, O; Halperin, JL; Hart, RG; Kronmal, RA; Man-Son-Hing, M; McBride, R, 2000) |
| " In patients with arterial or venous thrombosis, there is a high rate of recurrence during the two first years except if high-dose warfarin was used (i." | 4.80 | [Aspirin and antiphospholipid syndrome]. ( Blétry, O; Hachulla, E; Hatron, PY; Piette, AM, 2000) |
| " These results indicate that clopidogrel is more effective and safer than aspirin in reducing adverse cardiovascular events in patients with atherosclerosis." | 3.79 | Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Creager, MA, 1998) |
| "Patients who have had a recent transient ischemic attack (TIA) are at high risk for subsequent stroke." | 3.77 | Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly. ( Adams, HP; Gordon, DL, 1991) |
| "The possible additive antiplatelet effects of aspirin and clopidogrel have been explored in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) studies." | 3.72 | Long-term combination therapy with aspirin and clopidogrel. ( Cheung, BM; Cheung, G; Kumana, CR; Lauder, IJ, 2004) |
| "Using the CAPRIE database, we performed multivariate analyses for patients who had symptomatic atherosclerotic disease (ischemic stroke [IS] or myocardial infarction [MI]) in their medical history before enrollment in the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial." | 3.72 | Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2004) |
| "To explore the interactive effect of low-dosage aspirin (ASA) combined with perindopril (PER), on prostacyclin (PGI2), thromboxone A2 (TXA2), and norepinephrine (NE) in the blood of arteriosclerosis rabbit models and the cardiac function." | 3.72 | [Effect of aspirin combined with perindopril on prostacyclin, thromboxone A2, and norepinephrine in the blood of arteriosclerosis rabbit models and the cardiac function]. ( Li, J; Liu, LH; Zhuang, HP, 2003) |
| "As platelet hyperactivity is important in atherosclerosis and smoking, we hypothesized higher levels of soluble platelet membrane glycoprotein V (gpV) in 95 patients with peripheral artery disease (PAD) and 92 with coronary artery disease (CAD) compared to 99 healthy controls, and examined the effects of aspirin and of smoking two cigarettes on soluble gpV and platelet function." | 3.71 | Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis--the influence of aspirin and cigarette smoking. ( Blann, AD; Cazenave, JP; Galajda, P; Gurney, D; Lanza, F; Lip, GY; Moog, S, 2001) |
| "We evaluated both the effect of aspirin treatment (81 mg/day) on serum Lp(a) concentrations and the correlation between the degree of reduction in serum Lp(a) and the type of apo(a) isoform in 70 patients with coronary artery disease or cerebral infarction." | 3.71 | Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. ( Aihara, K; Akaike, M; Azuma, H; Hayashi, I; Iuchi, T; Kagawa, A; Kanagawa, Y; Matsumoto, K; Matsumoto, T; Nishiuchi, T; Takamori, N; Tamura, K; Yoshida, T, 2002) |
| "108 male rabbits, aged 6 months, with experimental hypercholesterolemia and experimental abdominal aortic lesioning received different regimen of antiatherosclerotic treatment; 36 of them were treated with isradipine, a dihydropyridine calcium antagonist (0." | 3.68 | Concomitant aspirin treatment abolishes the antiatherosclerotic effects of the calcium channel blocker isradipine mediated by PGI2. ( Angelberger, P; Gerakakis, A; Keiler, A; Lupattelli, G; Pirich, C; Sinzinger, H; Virgolini, I, 1992) |
| "Thromboxane A2 (TXA2) biosynthesis was studied in healthy subjects, patients with chronic cerebral infarction, patients under chronic aspirin treatment and patients with atrial fibrillation." | 3.68 | Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction. ( Hayashi, Y; Nakahama, H; Nakanishi, T; Shimizu, S; Sugita, M; Takiguchi, A; Uyama, O; Yamamoto, S, 1992) |
| "The proliferation of aortic smooth muscle cells (ASMC) of Wistar rats, impaired by risk factors such as arterial hypertension, diabetes mellitus, atherogenic diet and staphylolysin injections and of normal Wistar rats treated with antirheumatic drugs such as prednisolone and acetylsalicylic acid was investigated." | 3.66 | Effect of risk factors and antirheumatic drugs on the proliferation of aortic wall cells. ( Hauss, WH; Mey, J; Schulte, H, 1979) |
| "Ciprofibrate did not inhibit thromboxane B 2 synthesis in platelets." | 2.70 | Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects. ( Cibulová, L; Dzúrik, R; Gajdos, M; Huttová, D; Krivosíková, Z; Mongiellová, V; Spustová, V, 2001) |
| "Pravastatin was added to the drug regimen for those who needed to reduce LDL cholesterol to recommended levels." | 2.69 | Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. ( Applegate, WB; Crouse, JR; Davis, KB; Egan, D; Elam, MB; Garg, R; Herd, JA; Hunninghake, DB; Johnson, WC; Kennedy, JW; Kostis, JB; Sheps, DS, 2000) |
| "Only aspirin has been evaluated in the setting of primary prevention and it seems to be ineffective in preventing cerebral infarction." | 2.68 | [Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors]. ( Canaple, S; Rosa, A, 1996) |
| "Patients with asymptomatic internal carotid artery stenosis exceeding 60% reduction in diameter who are acceptable candidates for elective operation may be considered for CEA if the combined arteriographic and surgical complication rates are 3% or less." | 2.68 | An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. ACAS Investigators. Asymptomatic Carotid Atherosclerosis Study. ( Broderick, JP; Cohen, SN; Dempsey, RJ; Ernst, CB; Hosking, JD; Moore, WS; Robertson, JT; Toole, JF; Young, B, 1996) |
| "Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events." | 2.68 | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. ( , 1996) |
| " It is suggested that the effect of aspirin in low dosage on platelet aggregation might be ineffective in many patients without control of aspirin hydrolysis velocity in blood." | 2.67 | Dose-dependent aspirin hydrolysis and platelet aggregation in patients with atherosclerosis. ( Akopov, SS; Gabrielian, ES; Grigorian, GS, 1992) |
| "For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched June 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 5)." | 2.52 | Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. ( Acosta, S; Bedenis, R; Lethaby, A; Maxwell, H; Prins, MH, 2015) |
| "Vascular dementia is one of the most frequently occurring dementia syndromes." | 2.42 | [Vascular dementia]. ( de Leeuw, FE; van Gijn, J, 2004) |
| "Late-onset sporadic Alzheimer's disease is a heterogeneous disorder." | 2.42 | Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. ( Casserly, I; Topol, E, 2004) |
| " These results demonstrated that long-term administration of clopidogrel was effective in preventing ischaemic events in patients with atherosclerotic vascular disease including PAD." | 2.41 | Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy. ( Hiatt, WR, 2002) |
| "Aspirin has nonplatelet-mediated effects that contribute to its efficacy in the primary and secondary prevention of coronary events." | 2.41 | Nonplatelet-mediated effects of aspirin. ( Aude, YW; Mehta, JL, 2002) |
| "Chronic hyperglycemia is then added to these risk markers." | 2.40 | Multifactorial aspects of the treatment of the type II diabetic patient. ( Colwell, JA, 1997) |
| " This explains the different dosage requirements of aspirin as an antithrombotic (COX-1) and an anti-inflammatory drug (COX-2), respectively." | 2.40 | Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. ( Schrör, K, 1997) |
| "In children and young adults, amaurosis fugax is a benign condition." | 2.38 | Atherosclerotic carotid disease and the eye. ( Breen, LA, 1991) |
| " The controversies of dosage high (= 1,500 mg/d) or low (= 20-30 mg/d) are opposed by the concept of the individual dosage via the ASA-test." | 2.38 | [Anticoagulants and inhibitors of thrombocyte function in the long-term treatment of arteriosclerosis]. ( Heine, H; Norden, C, 1989) |
| " The majority of patients were given aspirin 1300 mg daily, but the optimum dosage was not properly evaluated." | 2.37 | The role of arachidonic acid metabolites in cardiovascular homeostasis. Biochemical, histological and clinical cardiovascular effects of non-steroidal anti-inflammatory drugs and their interactions with cardiovascular drugs. ( Goodman, DS, 1987) |
| " Long term administration of "antiplatelet drugs" to affect the rate of development of atherosclerosis seems neither feasible nor desirable." | 2.37 | The role of platelets in the development and complications of atherosclerosis. ( Mustard, JF; Packham, MA, 1986) |
| "Transient ischemic attacks are associated with a 30 to 35 percent risk of stroke within five years of the initial episode." | 2.37 | Carotid surgery in stroke prevention. ( Busuttil, RW; Sheng, FC, 1986) |
| " Among the anti-aggregant agents, only Aspirin at high dosage (1 to 1." | 2.37 | [The fate of patients with carotid stenosis. Comparative study, based on the literature, of their natural history and evolution under medical treatment or following endarterectomy]. ( Bachet, P; Ninet, J; Pasquier, J, 1985) |
| " Long term use of these drugs may prevent deterioration in those patients with progressive disease, and controlled trials on this aspect of treatment are now required." | 2.36 | Can drugs help patients with lower limb ischaemia? ( Bell, PR; Boobis, LH, 1982) |
| "Atherothrombosis is associated with the presence of a microinflammatory response, usually monitored by the use of C-reactive protein (CRP) measurements." | 1.33 | Lack of significant effect of low doses of aspirin on the concentrations of C-reactive protein in a group of individuals with atherothrombotic risk factors and vascular events. ( Ben Assayag, E; Berliner, S; Bornstein, NM; Melamed, S; Rogowski, O; Shapira, I; Shirom, A; Toker, S, 2006) |
| "Arteriosclerosis is the main cause of lacunar CVA and IOMP." | 1.33 | Clinical characteristics of patients with ischemic ocular nerve palsies and lacunar brain infarcts: a retrospective comparative study. ( Goldhammer, Y; Hartmann, B; Kessler, A; Pollak, L; Rabey, MJ, 2005) |
| "No or only a mild restenosis developed in 27 patients." | 1.32 | Clinical and angiographic outcome after interventional treatment of the iliac arteries with a new carbofilm coated stent: preliminary results. ( Butz, B; Feuerbach, S; Lenhart, M; Link, J; Paetzel, C; Pfister, K; Schleicher, T; Stern, U, 2004) |
| "Arterial thrombosis is initiated following lesion of the vessel wall, either through rupture of an atherosclerotic plaque containing lipids, adhesive proteins and tissue factor or after angioplasty exposing the thrombogenic subendothelial matrix." | 1.32 | [Platelets and arterial thrombosis]. ( Cazenave, JP; Gachet, C; Lanza, F; Wiesel, ML, 2003) |
| "However, systemic study of thrombus formation in vein grafts is still lacking, and few effective techniques are available to prevent this event." | 1.32 | Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection. ( Hu, Y; Mayr, U; Thompson, WD; Torsney, E; Xu, Q; Zou, Y, 2004) |
| "Aspirin has potent antiinflammatory properties and attenuates atherosclerosis in apolipoprotein-E-deficient mice fed a high-fat, high-cholesterol diet." | 1.32 | Aspirin attenuates the initiation but not the progression of atherosclerosis in apolipoprotein E-deficient mice fed a high-fat, high-cholesterol diet. ( Camps, J; Ferré, N; Joven, J; Riu, F; Tous, M; Vilella, E, 2004) |
| "Aspirin treatment attenuated smoking-induced changes in plaque composition." | 1.31 | Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. ( Cercek, B; Chyu, KY; Dimayuga, P; Fishbein, MC; Kangavari, S; Matetzky, S; Shah, PK; Tani, S; Xu, H; Yano, J, 2000) |
| " It is indicated, at a dosage of 75 mg/day, for the reduction of atherosclerotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction or established peripheral vascular disease." | 1.31 | [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. ( Scheen, AJ, 2001) |
| "Ciprofibrate was most effective in lowering the levels of triacylglycerids (-41%) and VLDL-cholesterol (-34%), but effectively lowered also the values of total cholesterol and LDL-cholesterol." | 1.30 | [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia]. ( Cibulova, L; Fedelesova, V; Gajdos, M; Huttova, D; Krivosikova, Z; Mongiellova, V; Polak, F, 1999) |
| "015), and chronic intake of nitrates (P<0." | 1.30 | Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. ( Beckmann, R; Binder, BR; Geppert, A; Graf, S; Hornykewycz, S; Huber, K; Schuster, E, 1998) |
| "The aspirin dose was 40 mg/d." | 1.30 | Both dietary fish-oil supplementation and aspirin fail to inhibit atherosclerosis in long-term vein bypass grafts in moderately hypercholesterolemic nonhuman primates. ( Almassi, GH; Boerboom, LE; Olinger, GN; Skrinska, VA, 1997) |
| "During reactive hyperemia, plasma endothelin was reduced in normal subjects (-1." | 1.30 | Postischemic hyperemia in subjects with lower limbs obstructive arteriopathy: role of PGI2 and endothelin. ( Arosio, E; Lechi, A; Minuz, P; Pancera, P; Ribul, M; Rossi, L, 1997) |
| "The extent of carotid atherosclerosis was determined by real-time B-mode ultrasonography." | 1.29 | Risk factors for carotid atherosclerosis and platelet activation. ( Matsui, Y; Michishita, H; Shimizu, S; Sugita, M; Uyama, O, 1994) |
| "Aspirin treatment failed in 21 patients with severe carotid stenosis (greater than 75% stenosis)." | 1.28 | Patterns of failure of aspirin treatment in symptomatic atherosclerotic carotid artery disease. ( Chen, TL; Chyatte, D, 1990) |
| "Patients with transient ischemic attacks (TIA) were previously shown to have high plasma values of thiobarbituric acid-reactive substances (TBA-RS)." | 1.28 | Blood lipid peroxides in TIA: relation to platelet function and metabolic profile. ( Alessandri, C; Balsano, F; Caliendo, C; Censi, C; Germani, M; Ghiselli, A; Servi, M; Violi, F, 1989) |
| " Here we report on a study including 41 patients with peripheral arterial disease and/or coronary heart disease before treatment and after receiving ASA in an individually controlled dosage regimen." | 1.27 | Individually controlled acetylsalicyclic acid (ASA) in the long-term treatment of patients with arteriosclerosis. ( Heine, H; Misselwitz, F; Norden, C, 1988) |
| " Dose-response platelet aggregometry detected no differences between groups in the sensitivity of platelets to adenosine diphosphate (ADP), collagen, and epinephrine." | 1.27 | Etiologic factors for recurrent carotid artery stenosis. ( Clagett, GP; Hutton, JE; McDonald, PT; Olson, DW; Rich, NM; Salander, JM; Youkey, JR, 1983) |
| " This case suggests that the chronic intake of large doses of aspirin cannot prevent arterial disorders." | 1.26 | Congenital deficiency of cyclo-oxygenase in a woman with generalized atherosclerosis. ( Altorjay, I; Boda, Z; Pfliegler, G; Rak, K; Tamás, E, 1981) |
| "2." | 1.26 | Study of drugs affecting cholesterol-induced atherosclerosis in rabbits. ( Kim, DN; Kwak, YS; Lee, KT, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 161 (41.49) | 18.7374 |
| 1990's | 108 (27.84) | 18.2507 |
| 2000's | 112 (28.87) | 29.6817 |
| 2010's | 7 (1.80) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moncada, S | 2 |
| Vane, JR | 3 |
| Koga, Y | 1 |
| Kihara, Y | 1 |
| Okada, M | 1 |
| Inoue, Y | 1 |
| Tochizawa, S | 1 |
| Toga, K | 1 |
| Tachibana, K | 1 |
| Kimura, Y | 1 |
| Nishi, T | 1 |
| Hidaka, H | 1 |
| Severino, M | 1 |
| Giacomini, T | 1 |
| Verrina, E | 1 |
| Prato, G | 1 |
| Rossi, A | 1 |
| Füessl, HS | 1 |
| Stiefelhagen, P | 1 |
| Bedenis, R | 1 |
| Lethaby, A | 1 |
| Maxwell, H | 1 |
| Acosta, S | 1 |
| Prins, MH | 1 |
| Loew, D | 3 |
| Belz, GG | 1 |
| Müller-Ehmsen, J | 1 |
| Erdmann, E | 1 |
| Galesic, M | 1 |
| Garcia-Retamero, R | 1 |
| Gigerenzer, G | 1 |
| Patrono, C | 4 |
| Baigent, C | 2 |
| Preobrazhenskiĭ, DV | 1 |
| Sidorenko, BA | 1 |
| Fettser, DV | 1 |
| Batyraliev, TA | 1 |
| Niiazova-Karben, ZA | 1 |
| Besnili, F | 1 |
| Tamura, I | 1 |
| Fujita, T | 2 |
| Tsumura, H | 1 |
| Morita, Y | 1 |
| Yoshida, M | 1 |
| Toyonaga, T | 1 |
| Hirano, S | 1 |
| Inokuchi, H | 1 |
| Kutsumi, H | 1 |
| Azuma, T | 1 |
| Wallace, JL | 1 |
| Ignarro, LJ | 1 |
| Fiorucci, S | 1 |
| Akaike, M | 1 |
| Azuma, H | 1 |
| Kagawa, A | 1 |
| Matsumoto, K | 1 |
| Hayashi, I | 1 |
| Tamura, K | 1 |
| Nishiuchi, T | 1 |
| Iuchi, T | 1 |
| Takamori, N | 1 |
| Aihara, K | 1 |
| Yoshida, T | 1 |
| Kanagawa, Y | 1 |
| Matsumoto, T | 1 |
| Cyrus, T | 2 |
| Sung, S | 1 |
| Zhao, L | 2 |
| Funk, CD | 1 |
| Tang, S | 1 |
| Praticò, D | 2 |
| Napoli, C | 1 |
| Ackah, E | 1 |
| De Nigris, F | 1 |
| Del Soldato, P | 1 |
| D'Armiento, FP | 1 |
| Crimi, E | 1 |
| Condorelli, M | 1 |
| Sessa, WC | 1 |
| Lee, TH | 1 |
| Zhdanova, IV | 1 |
| Tsvirenko, SV | 1 |
| Barats, SS | 1 |
| Smolenskaia, OG | 1 |
| Volkova, RF | 1 |
| Serezhenko, TO | 1 |
| Brinkman, WT | 1 |
| Terramani, TT | 1 |
| Najibi, S | 1 |
| Chaikof, EL | 1 |
| Lévesque, H | 2 |
| Veillard, NR | 1 |
| Mach, F | 1 |
| Aude, YW | 1 |
| Mehta, JL | 2 |
| Lecompte, T | 1 |
| Cha, JK | 1 |
| Jeong, MH | 1 |
| Lee, KM | 1 |
| Bae, HR | 1 |
| Lim, YJ | 1 |
| Park, KW | 1 |
| Cheon, SM | 1 |
| Sellmayer, A | 1 |
| Limmert, T | 1 |
| Hoffmann, U | 2 |
| Ziegler, BK | 1 |
| Rasmussen, LH | 1 |
| Kristensen, SD | 1 |
| Hildebrandt, PR | 1 |
| Nielsen, HK | 1 |
| Husted, SE | 2 |
| Tracy, RP | 2 |
| Tamminen, M | 1 |
| Lassila, R | 2 |
| Westerbacka, J | 1 |
| Vehkavaara, S | 1 |
| Yki-Järvinen, H | 1 |
| Meir, K | 1 |
| Leitersdorf, E | 1 |
| Hennekens, CH | 3 |
| Zhuang, HP | 1 |
| Li, J | 1 |
| Liu, LH | 1 |
| Gere, J | 1 |
| Minier, D | 1 |
| Osseby, GV | 1 |
| Couvreur, G | 1 |
| Moreau, T | 1 |
| Giroud, M | 1 |
| JENNINGS, GH | 1 |
| Cazenave, JP | 2 |
| Gachet, C | 1 |
| Lanza, F | 2 |
| Wiesel, ML | 1 |
| Nakajima, M | 1 |
| Kimura, K | 1 |
| Minematsu, K | 2 |
| Saito, K | 1 |
| Takada, T | 1 |
| Tanaka, M | 1 |
| Ringleb, PA | 2 |
| Bhatt, DL | 2 |
| Hirsch, AT | 1 |
| Topol, EJ | 3 |
| Hacke, W | 1 |
| Drouet, L | 1 |
| Schröder, S | 1 |
| Grübler, B | 1 |
| Diener, HC | 1 |
| Bogousslavsky, J | 3 |
| Brass, LM | 1 |
| Cimminiello, C | 1 |
| Csiba, L | 1 |
| Kaste, M | 1 |
| Leys, D | 2 |
| Matias-Guiu, J | 1 |
| Rupprecht, HJ | 1 |
| Rao, U | 1 |
| Weston, C | 1 |
| Rodgers, JE | 1 |
| Steinhubl, SR | 1 |
| Casserly, I | 1 |
| Topol, E | 1 |
| Wong, S | 1 |
| Appleberg, M | 1 |
| Ward, CM | 1 |
| Lewis, DR | 1 |
| Torsney, E | 1 |
| Mayr, U | 1 |
| Zou, Y | 1 |
| Thompson, WD | 1 |
| Hu, Y | 1 |
| Xu, Q | 1 |
| Yang, YY | 1 |
| Hu, CJ | 1 |
| Chang, SM | 1 |
| Tai, TY | 1 |
| Leu, SJ | 1 |
| Jagroop, IA | 1 |
| Matsagas, MI | 1 |
| Geroulakos, G | 1 |
| Mikhailidis, DP | 1 |
| Schellinger, PD | 1 |
| Schwark, C | 1 |
| de Leeuw, FE | 1 |
| van Gijn, J | 1 |
| Tous, M | 1 |
| Ferré, N | 2 |
| Vilella, E | 2 |
| Riu, F | 1 |
| Camps, J | 2 |
| Joven, J | 2 |
| Taubert, D | 1 |
| Berkels, R | 1 |
| Grosser, N | 1 |
| Schröder, H | 1 |
| Gründemann, D | 1 |
| Schömig, E | 1 |
| Lewis, SC | 1 |
| Warlow, CP | 1 |
| Kanazawa, M | 1 |
| Wada, Y | 1 |
| Ohno, T | 1 |
| In, H | 1 |
| Yahata, K | 1 |
| Izumi, J | 1 |
| Tanaka, H | 1 |
| Ito, S | 1 |
| Ueno, M | 1 |
| Nakano, M | 1 |
| Gejyo, F | 1 |
| Tran, H | 1 |
| Anand, SS | 1 |
| Butz, B | 1 |
| Paetzel, C | 1 |
| Stern, U | 1 |
| Schleicher, T | 1 |
| Pfister, K | 1 |
| Link, J | 1 |
| Feuerbach, S | 1 |
| Lenhart, M | 1 |
| Kouraklis, G | 1 |
| Patapis, P | 1 |
| Misiakos, E | 1 |
| Glinavou, A | 1 |
| Sioka, C | 1 |
| Karayiannakos, PE | 1 |
| Löbner, K | 1 |
| Füchtenbusch, M | 1 |
| Kumana, CR | 1 |
| Cheung, G | 1 |
| Lauder, IJ | 1 |
| Cheung, BM | 1 |
| Moussouttas, M | 1 |
| Pollak, L | 1 |
| Kessler, A | 1 |
| Rabey, MJ | 1 |
| Hartmann, B | 1 |
| Goldhammer, Y | 1 |
| Shanks, M | 1 |
| Holmes, DT | 1 |
| Cermakova, L | 1 |
| Frohlich, J | 1 |
| Savi, P | 1 |
| Herbert, JM | 1 |
| Kiss, RG | 1 |
| Ariesen, MJ | 1 |
| Tangelder, MJ | 1 |
| Lawson, JA | 1 |
| Eikelboom, BC | 1 |
| Grobbee, DE | 2 |
| Algra, A | 2 |
| Baba, Y | 1 |
| Hentschel, K | 1 |
| Freeman, WD | 1 |
| Broderick, DF | 1 |
| Wszolek, ZK | 1 |
| Norris, JW | 1 |
| Costenbader, KH | 1 |
| Karlson, EW | 1 |
| Gall, V | 1 |
| de Pablo, P | 1 |
| Finckh, A | 1 |
| Lynch, M | 1 |
| Bermas, B | 1 |
| Schur, PH | 1 |
| Liang, MH | 1 |
| García Rodríguez, LA | 1 |
| Landolfi, R | 1 |
| Billett, HH | 1 |
| Gray, L | 1 |
| Leonardi-Bee, J | 1 |
| Weaver, CS | 1 |
| Heptinstall, S | 2 |
| Bath, PM | 1 |
| Rogowski, O | 1 |
| Shapira, I | 1 |
| Ben Assayag, E | 1 |
| Bornstein, NM | 1 |
| Toker, S | 1 |
| Melamed, S | 1 |
| Shirom, A | 1 |
| Berliner, S | 1 |
| Faxon, DP | 3 |
| Nesto, RW | 1 |
| Gaciong, Z | 1 |
| Toyoda, K | 1 |
| Okada, Y | 1 |
| Ibayashi, S | 1 |
| Inoue, T | 1 |
| Yasumori, K | 1 |
| Fukui, D | 1 |
| Uwatoko, T | 1 |
| Makihara, N | 1 |
| Fontana, P | 1 |
| Jamieson, DG | 1 |
| Lorenzen, ND | 1 |
| Eldrup, N | 1 |
| Laustsen, J | 1 |
| Thorngren, M | 1 |
| Gustafson, A | 1 |
| Breddin, K | 1 |
| Uberla, K | 1 |
| Murray, PD | 1 |
| Garnic, JD | 1 |
| Bettmann, MA | 1 |
| Baluda, VP | 3 |
| Lukoianova, TI | 2 |
| Baluda, MV | 1 |
| Branson, HE | 1 |
| Endo, Y | 1 |
| Fagin, AR | 1 |
| Schlutz, M | 1 |
| López-Campos, JL | 1 |
| Piñero, J | 1 |
| Lasierra, J | 5 |
| Navas, P | 1 |
| Moreno, J | 1 |
| Cobo, R | 1 |
| Bousser, MG | 3 |
| Eschwège, E | 1 |
| Haguenau, M | 1 |
| Lefauconnier, JM | 1 |
| Thibult, N | 1 |
| Touboul, D | 1 |
| Touboul, PJ | 1 |
| Cunningham, DA | 1 |
| Kumar, B | 1 |
| Siegel, BA | 1 |
| Gilula, LA | 1 |
| Totty, WG | 1 |
| Welch, MJ | 1 |
| Bollinger, A | 2 |
| Biland, L | 1 |
| Brunner, U | 1 |
| Kappert, A | 1 |
| Krähenbühl, B | 1 |
| Mahler, F | 1 |
| Monti, M | 1 |
| Nachbur, B | 1 |
| Schneider, E | 2 |
| Widmer, LK | 1 |
| Sanborn, TA | 1 |
| Haudenschild, CC | 2 |
| Ryan, TJ | 2 |
| Packham, MA | 5 |
| Mustard, JF | 5 |
| de Gaetano, G | 1 |
| Bastard, J | 1 |
| Goas, JY | 1 |
| Boobis, LH | 1 |
| Bell, PR | 1 |
| Weksler, BB | 2 |
| Pett, SB | 1 |
| Alonso, D | 1 |
| Richter, RC | 1 |
| Stelzer, P | 1 |
| Subramanian, V | 1 |
| Tack-Goldman, K | 1 |
| Gay, WA | 1 |
| Mehta, J | 3 |
| Eichner, ER | 1 |
| Viinikka, L | 3 |
| Díez, MM | 2 |
| Fernández, A | 3 |
| Viladés, E | 3 |
| Gil, M | 3 |
| Velázquez, E | 3 |
| Cain, TD | 1 |
| Wood, JS | 1 |
| Beard, OW | 1 |
| Bastida, E | 1 |
| Salokannel, J | 1 |
| Ylikorkala, O | 1 |
| Saudeau, D | 1 |
| Autret, A | 2 |
| Das, UN | 1 |
| Colwell, JA | 4 |
| Halushka, PV | 1 |
| Gryglewski, RJ | 2 |
| Green, D | 1 |
| Kucuk, O | 1 |
| Haring, O | 1 |
| Dyer, A | 1 |
| Clagett, GP | 1 |
| Rich, NM | 1 |
| McDonald, PT | 1 |
| Salander, JM | 1 |
| Youkey, JR | 1 |
| Olson, DW | 1 |
| Hutton, JE | 1 |
| Brunt, JH | 1 |
| Kim, DN | 2 |
| Lee, KT | 2 |
| Schmee, J | 1 |
| Thomas, WA | 1 |
| Kinlough-Rathbone, RL | 3 |
| Mehta, P | 1 |
| Weber, PC | 1 |
| Siess, W | 1 |
| Scherer, B | 1 |
| Held, E | 1 |
| Witzgall, H | 1 |
| Lorenz, R | 1 |
| Bonchek, LI | 1 |
| Boerboom, LE | 2 |
| Olinger, GN | 2 |
| Pepper, JR | 2 |
| Munns, J | 1 |
| Hutchinson, L | 1 |
| Kissebah, AH | 1 |
| Kelton, JG | 1 |
| Blajchman, MA | 1 |
| Fuster, V | 4 |
| Chesebro, JH | 5 |
| Herman, AG | 1 |
| Sirtori, CR | 1 |
| Tremoli, E | 2 |
| Paoletti, R | 2 |
| Sloan, RW | 1 |
| Delgado, G | 1 |
| Martínez-Lage, JM | 1 |
| Viteri, C | 1 |
| Saunders, RN | 1 |
| Verdecchia, P | 1 |
| Jouve, R | 1 |
| Juhan-Vague, I | 1 |
| Aillaud, M | 1 |
| Serment-Jouve, M | 1 |
| Payan, H | 1 |
| Malinow, MR | 1 |
| Lakin, KM | 1 |
| Pabvlishchuk, SA | 1 |
| Deianov, I | 2 |
| Nedelkovskiĭ, I | 1 |
| Ashkinazi, IIa | 1 |
| Boda, Z | 1 |
| Tamás, E | 1 |
| Altorjay, I | 1 |
| Pfliegler, G | 1 |
| Rak, K | 2 |
| Koster, JK | 1 |
| Tryka, AF | 1 |
| H'Doubler, P | 1 |
| Collins, JJ | 1 |
| Clopath, P | 1 |
| Paredero Del Bosque Martin, V | 1 |
| Robicsek, F | 1 |
| Isogaya, M | 1 |
| Yamada, N | 1 |
| Koike, H | 1 |
| Ueno, Y | 1 |
| Kumagai, H | 1 |
| Ochi, Y | 1 |
| Okazaki, S | 1 |
| Nishio, S | 1 |
| Frishman, WH | 2 |
| Burns, B | 1 |
| Atac, B | 1 |
| Alturk, N | 1 |
| Altajar, B | 1 |
| Lerrick, K | 1 |
| Numano, F | 1 |
| Kishi, Y | 1 |
| Ashikaga, T | 1 |
| Hata, A | 1 |
| Makita, T | 1 |
| Watanabe, R | 1 |
| Lyle, EM | 1 |
| Conner, MW | 1 |
| Connolly, TM | 1 |
| Vlasuk, GP | 1 |
| Lynch, JL | 1 |
| Mohan, CR | 1 |
| Sharp, WJ | 1 |
| Hoballah, JJ | 1 |
| Kresowik, TF | 1 |
| Schueppert, MT | 1 |
| Corson, JD | 1 |
| Lovell, R | 1 |
| Eritsland, J | 1 |
| Arnesen, H | 1 |
| Seljeflot, I | 1 |
| Kierulf, P | 1 |
| Uyama, O | 2 |
| Matsui, Y | 1 |
| Shimizu, S | 2 |
| Michishita, H | 1 |
| Sugita, M | 2 |
| Schipper, JP | 2 |
| McCann, RL | 1 |
| Sun, YP | 1 |
| Zhu, BQ | 1 |
| Sievers, RE | 1 |
| Isenberg, WM | 1 |
| Parmley, WW | 1 |
| Cleland, JG | 2 |
| Krikler, DM | 1 |
| Sarin, S | 1 |
| Shami, SK | 1 |
| Cheatle, TR | 1 |
| Bearn, P | 1 |
| Scurr, JH | 1 |
| Coleridge Smith, PD | 1 |
| Wu, KK | 1 |
| Hertzer, NR | 1 |
| Smith, MJ | 1 |
| Allen, KG | 1 |
| Norman, JF | 1 |
| Harris, MA | 1 |
| Miller, CW | 1 |
| Frey, JL | 1 |
| Shahar, E | 1 |
| Folsom, AR | 1 |
| Romm, FJ | 1 |
| Bisgard, KM | 1 |
| Metcalf, PA | 1 |
| Crum, L | 1 |
| McGovern, PG | 1 |
| Hutchinson, RG | 1 |
| Heiss, G | 1 |
| Ricou, FJ | 1 |
| Arroyo, JF | 1 |
| Castillo, V | 1 |
| Vuadens, P | 1 |
| Leu, AJ | 1 |
| Blum, A | 1 |
| Miller, HI | 1 |
| Young, B | 1 |
| Moore, WS | 2 |
| Robertson, JT | 2 |
| Toole, JF | 3 |
| Ernst, CB | 1 |
| Cohen, SN | 1 |
| Broderick, JP | 1 |
| Dempsey, RJ | 1 |
| Hosking, JD | 1 |
| Badimon, J | 1 |
| Fallon, JT | 1 |
| Pancera, P | 1 |
| Minuz, P | 1 |
| Rossi, L | 1 |
| Ribul, M | 1 |
| Arosio, E | 1 |
| Lechi, A | 1 |
| Rosa, A | 1 |
| Canaple, S | 1 |
| Keil, Tu | 1 |
| Polasek, J | 1 |
| Laperche, T | 1 |
| Laurian, C | 1 |
| Roudaut, R | 1 |
| Steg, PG | 1 |
| Schrör, K | 2 |
| Almassi, GH | 1 |
| Skrinska, VA | 1 |
| Hankey, GJ | 1 |
| Manning, WJ | 1 |
| Terano, T | 1 |
| Hirai, A | 1 |
| Shiina, T | 1 |
| Tamura, Y | 1 |
| Saitoh, Y | 1 |
| Ridker, PM | 3 |
| Roitman-Johnson, B | 1 |
| Stampfer, MJ | 2 |
| Allen, J | 1 |
| Piazza, V | 1 |
| Rulli, F | 1 |
| Cushman, M | 1 |
| Husain, S | 1 |
| Andrews, NP | 1 |
| Mulcahy, D | 1 |
| Panza, JA | 1 |
| Quyyumi, AA | 2 |
| Tijssen, JG | 1 |
| Ferguson, JJ | 2 |
| Gonzalez, ER | 3 |
| Kannel, WB | 1 |
| Olin, JW | 1 |
| Raps, EC | 1 |
| Geppert, A | 1 |
| Graf, S | 1 |
| Beckmann, R | 1 |
| Hornykewycz, S | 1 |
| Schuster, E | 1 |
| Binder, BR | 1 |
| Huber, K | 1 |
| Sloop, GD | 1 |
| Kannewurf, BS | 1 |
| Speir, E | 1 |
| Yu, ZX | 1 |
| Ferrans, VJ | 1 |
| Riggs, PN | 1 |
| DeWeese, JA | 1 |
| Creager, MA | 1 |
| Blackshear, JL | 1 |
| Zabalgoitia, M | 1 |
| Pennock, G | 1 |
| Fenster, P | 1 |
| Strauss, R | 1 |
| Halperin, J | 1 |
| Asinger, R | 1 |
| Pearce, LA | 1 |
| Violi, F | 2 |
| Balsano, F | 2 |
| Cesarone, MR | 1 |
| Laurora, G | 1 |
| DeSanctis, MT | 1 |
| Incandela, L | 1 |
| Fugazza, L | 1 |
| Girardello, R | 1 |
| Poli, A | 1 |
| Peracino, L | 1 |
| Ambrosoli, L | 1 |
| Belcaro, G | 1 |
| Hermann, M | 2 |
| Kapiotis, S | 2 |
| Hofbauer, R | 2 |
| Seelos, C | 2 |
| Held, I | 2 |
| Gmeiner, B | 1 |
| Brown, N | 1 |
| May, JA | 1 |
| Wilcox, RG | 1 |
| Allan, LM | 1 |
| Wilson, AM | 1 |
| Kiff, PS | 1 |
| Zusman, RM | 1 |
| Comerota, A | 1 |
| Hartmann, JR | 1 |
| Massin, EK | 1 |
| Raps, E | 1 |
| Wolf, PA | 1 |
| van de Vijver, LP | 1 |
| Kardinaal, AF | 1 |
| van Duyvenvoorde, W | 1 |
| Kruijssen, DA | 1 |
| van Poppel, G | 1 |
| Princen, HM | 1 |
| Fuglsang, J | 1 |
| Ravn, HB | 1 |
| Toft, GE | 1 |
| Thorwest, M | 1 |
| Hjortdal, VE | 1 |
| Harker, LA | 5 |
| Boissel, JP | 1 |
| Pilgrim, AJ | 1 |
| Gent, M | 3 |
| Wilson, JM | 1 |
| Ikeda, Y | 1 |
| Carrier, M | 1 |
| Rivard, M | 1 |
| Kostuk, W | 1 |
| Latter, D | 1 |
| Daly, P | 1 |
| Davies, R | 1 |
| Teo, K | 1 |
| Gudas, V | 1 |
| Sullivan, J | 1 |
| White, M | 1 |
| Gajdos, M | 2 |
| Fedelesova, V | 1 |
| Mongiellova, V | 2 |
| Cibulova, L | 2 |
| Huttova, D | 2 |
| Polak, F | 1 |
| Krivosikova, Z | 2 |
| Stanford, SJ | 1 |
| Mitchell, JA | 1 |
| Hart, RG | 1 |
| Halperin, JL | 1 |
| McBride, R | 1 |
| Benavente, O | 1 |
| Man-Son-Hing, M | 1 |
| Kronmal, RA | 1 |
| Exner, M | 1 |
| Speiser, W | 1 |
| Gmeiner, BM | 1 |
| Randi, ML | 2 |
| Rossi, C | 1 |
| Fabris, F | 2 |
| Girolami, A | 2 |
| Tanasescu, S | 1 |
| Thuillez, C | 1 |
| Hachulla, E | 1 |
| Piette, AM | 1 |
| Hatron, PY | 1 |
| Blétry, O | 1 |
| Walvoort, HC | 1 |
| Einecke, D | 1 |
| Cayatte, AJ | 1 |
| Du, Y | 1 |
| Oliver-Krasinski, J | 1 |
| Lavielle, G | 1 |
| Verbeuren, TJ | 1 |
| Cohen, RA | 1 |
| Matetzky, S | 1 |
| Tani, S | 1 |
| Kangavari, S | 1 |
| Dimayuga, P | 1 |
| Yano, J | 1 |
| Xu, H | 1 |
| Chyu, KY | 1 |
| Fishbein, MC | 1 |
| Shah, PK | 2 |
| Cercek, B | 1 |
| Stemme, V | 1 |
| Swedenborg, J | 1 |
| Claesson, H | 1 |
| Hansson, GK | 1 |
| Belton, O | 1 |
| Byrne, D | 1 |
| Kearney, D | 1 |
| Leahy, A | 1 |
| Fitzgerald, DJ | 1 |
| Albert, MA | 1 |
| Baker, WH | 1 |
| Howard, VJ | 1 |
| Howard, G | 1 |
| Garg, R | 1 |
| Elam, MB | 1 |
| Crouse, JR | 1 |
| Davis, KB | 1 |
| Kennedy, JW | 1 |
| Egan, D | 1 |
| Herd, JA | 1 |
| Hunninghake, DB | 1 |
| Johnson, WC | 1 |
| Kostis, JB | 1 |
| Sheps, DS | 1 |
| Applegate, WB | 1 |
| Masferrer, JL | 1 |
| Needleman, P | 1 |
| Li, H | 1 |
| FitzGerald, GA | 3 |
| Bennett, JS | 1 |
| Paul, A | 1 |
| Calleja, L | 1 |
| Osada, J | 1 |
| Mayayo, E | 1 |
| Langlois, M | 1 |
| Duprez, D | 2 |
| Delanghe, J | 1 |
| De Buyzere, M | 1 |
| Clement, DL | 2 |
| Egger, G | 1 |
| Burda, A | 1 |
| Obernosterer, A | 1 |
| Mitterhammer, H | 1 |
| Kager, G | 1 |
| Jürgens, G | 1 |
| Hofer, HP | 1 |
| Fabjan, JS | 1 |
| Pilger, E | 1 |
| Scheen, AJ | 1 |
| Kreuzer, J | 1 |
| Kübler, W | 1 |
| Blann, AD | 1 |
| Galajda, P | 1 |
| Gurney, D | 1 |
| Moog, S | 1 |
| Lip, GY | 1 |
| Spustová, V | 1 |
| Dzúrik, R | 1 |
| Nurden, P | 1 |
| Ndoko, S | 1 |
| Nurden, AT | 1 |
| Brown, JB | 1 |
| Delea, TE | 1 |
| Nichols, GA | 1 |
| Edelsberg, J | 1 |
| Elmer, PJ | 1 |
| Oster, G | 1 |
| de Ferranti, S | 1 |
| Rifai, N | 1 |
| Bredie, SJ | 1 |
| Wollersheim, HC | 1 |
| Verheugt, FW | 1 |
| Thien, T | 1 |
| Hiatt, WR | 1 |
| Libby, P | 1 |
| Uchiyama, S | 1 |
| Yamazaki, M | 1 |
| Iwata, M | 1 |
| Kiberd, BA | 1 |
| Rossignol, P | 1 |
| La Batida Alanore, A | 1 |
| Roueff, S | 1 |
| Bobrie, G | 1 |
| Plouin, PF | 1 |
| Robbins, M | 1 |
| Cohn, PF | 1 |
| Jobin, F | 1 |
| Marx, R | 1 |
| Heine, H | 5 |
| Norden, C | 6 |
| Heinemann, L | 1 |
| Stepanauskas, M | 1 |
| Pick, R | 1 |
| Chediak, J | 1 |
| Glick, G | 1 |
| Hollander, W | 1 |
| Kirkpatrick, B | 1 |
| Paddock, J | 1 |
| Colombo, M | 1 |
| Nagraj, S | 1 |
| Prusty, S | 1 |
| Hauss, WH | 1 |
| Mey, J | 1 |
| Schulte, H | 1 |
| Marcus, AJ | 1 |
| Gryglewski, R | 1 |
| Baumgartner, HR | 1 |
| Zicot, M | 1 |
| Pokrovskiĭ, AV | 2 |
| Dmitrieva, VA | 1 |
| Aleksandrova, NP | 2 |
| Kovalenko, VI | 3 |
| Il'in, SG | 1 |
| Hollmann, B | 1 |
| Fontana, A | 1 |
| De Mey, C | 1 |
| Wellens, D | 1 |
| Vanhoutte, PM | 1 |
| Barnett, HJ | 1 |
| Gingrich, RD | 1 |
| Hoak, JC | 1 |
| Grobe, T | 1 |
| Verstraete, M | 1 |
| Strano, A | 1 |
| Novo, S | 1 |
| McGiff, JC | 1 |
| Bailey, JM | 1 |
| Makheja, AN | 1 |
| Butler, J | 1 |
| Salata, K | 1 |
| Ciammaichella, A | 1 |
| Vergroesen, AJ | 1 |
| Gottenbos, JJ | 1 |
| ten Hoor, F | 1 |
| Rossi, EC | 1 |
| Evangelisti, GB | 1 |
| Faggioli, F | 1 |
| Garagnani, A | 1 |
| Lama, G | 1 |
| Kogut, MD | 1 |
| Radzivil, VF | 1 |
| Deykin, D | 1 |
| Tazaki, Y | 1 |
| Sawada, T | 1 |
| Hirsh, J | 2 |
| Genton, E | 3 |
| Duncan, GW | 1 |
| Pessin, MS | 1 |
| Mohr, JP | 2 |
| Adams, RD | 1 |
| O'Brien, JR | 2 |
| Höpker, WW | 1 |
| Hofmann, W | 1 |
| Weiss, J | 1 |
| Zimmermann, R | 1 |
| Walter, E | 1 |
| Dittmar, HA | 1 |
| Weizel, A | 1 |
| Ehresmann, U | 1 |
| Alemany, J | 1 |
| Moore, S | 1 |
| Kopasz, E | 1 |
| Prof Aiuto, G | 1 |
| Matsuo, T | 1 |
| Ooki, Y | 1 |
| Kwak, YS | 1 |
| Pirich, C | 1 |
| Lupattelli, G | 2 |
| Virgolini, I | 1 |
| Keiler, A | 2 |
| Gerakakis, A | 1 |
| Angelberger, P | 1 |
| Sinzinger, H | 4 |
| Nakanishi, T | 1 |
| Nakahama, H | 1 |
| Takiguchi, A | 1 |
| Hayashi, Y | 1 |
| Yamamoto, S | 1 |
| Ferroni, P | 1 |
| Gazzaniga, PP | 1 |
| Balelli, LA | 1 |
| Sandborn, T | 1 |
| Haudenschild, C | 1 |
| Valeri, R | 1 |
| Steffan, A | 1 |
| Avruscio, GP | 1 |
| Cordiano, I | 1 |
| Gunby, P | 1 |
| Fitscha, P | 2 |
| Rauscha, F | 1 |
| O'Grady, J | 2 |
| Akopov, SE | 1 |
| Gabrielian, ES | 2 |
| Wilcox, M | 1 |
| Janicek, MJ | 1 |
| Meyerovitz, M | 1 |
| Harrington, DP | 1 |
| Hollenberg, NK | 1 |
| Akopov, SS | 1 |
| Grigorian, GS | 1 |
| Gore, JM | 1 |
| Dalen, JE | 1 |
| Scriven, AJ | 1 |
| Lidbury, PS | 1 |
| Nathan, AW | 1 |
| Rudofsky, G | 3 |
| Ranft, J | 1 |
| Hirche, H | 2 |
| Badimon, L | 1 |
| Badimon, JJ | 1 |
| Ip, JH | 1 |
| Adams, HP | 1 |
| Gordon, DL | 1 |
| Hsiang, Y | 1 |
| White, RA | 1 |
| Kopchok, GE | 1 |
| Rosenbaum, D | 1 |
| Guthrie, C | 1 |
| Kao, J | 1 |
| Zhen, EZ | 1 |
| Peng, SK | 1 |
| Fragoso, M | 1 |
| Breen, LA | 1 |
| Landymore, RW | 1 |
| MacAulay, MA | 1 |
| Fris, J | 1 |
| Korbut, R | 1 |
| Ocetkiewicz, A | 1 |
| Dabros, W | 1 |
| Carlsson, I | 1 |
| Benthin, G | 1 |
| Petersson, AS | 1 |
| Wennmalm, A | 1 |
| Pramsohler, B | 1 |
| Scholz, H | 1 |
| Zeng, GY | 1 |
| Sun, YD | 1 |
| Tian, BH | 1 |
| Wang, Z | 1 |
| Hu, YH | 1 |
| An, Y | 1 |
| Nicolau, JC | 1 |
| Ramires, JA | 1 |
| Chyatte, D | 1 |
| Chen, TL | 1 |
| Mittal, SR | 1 |
| Mathur, AK | 1 |
| Tandon, R | 1 |
| Pang, S | 1 |
| Maderna, P | 1 |
| Hladovec, J | 1 |
| Reimann, H | 1 |
| Grunow, G | 1 |
| Misselwitz, F | 4 |
| Taube, C | 1 |
| Oates, JA | 1 |
| Kyrle, PA | 1 |
| Minar, E | 3 |
| Brenner, B | 1 |
| Eichler, HG | 1 |
| Heistinger, M | 1 |
| Marosi, L | 1 |
| Lechner, K | 1 |
| Gonzalez, J | 1 |
| Aza, MJ | 1 |
| Melon, J | 1 |
| Vazquez, E | 1 |
| Collado, PS | 1 |
| Castellarnau, C | 1 |
| Rutllant, M | 1 |
| Satta, MA | 1 |
| Scoppola, A | 1 |
| Melina, D | 1 |
| Guerrera, G | 2 |
| Capaldi, L | 1 |
| Folli, G | 1 |
| Adams, D | 1 |
| Sarris, GE | 1 |
| Fann, JI | 1 |
| Sokoloff, MH | 1 |
| Smith, DL | 1 |
| Loveday, M | 1 |
| Kosek, JC | 1 |
| Stephens, RJ | 1 |
| Cooper, AD | 1 |
| May, K | 1 |
| Willis, AL | 1 |
| Yeager, RA | 1 |
| Moneta, GL | 1 |
| McConnell, DB | 1 |
| Neuwelt, EA | 1 |
| Taylor, LM | 1 |
| Porter, JM | 1 |
| Alessandri, C | 1 |
| Ghiselli, A | 1 |
| Germani, M | 1 |
| Caliendo, C | 1 |
| Censi, C | 1 |
| Servi, M | 1 |
| Ingerman-Wojenski, CM | 1 |
| Silver, MJ | 1 |
| Gelman, JS | 1 |
| Ehringer, H | 2 |
| Dudczak, R | 2 |
| Schöfl, R | 1 |
| Jung, M | 1 |
| Koppensteiner, R | 1 |
| Ahmadi, R | 2 |
| Kretschmer, G | 1 |
| Miller, KP | 1 |
| Porenta, G | 1 |
| Riess, H | 1 |
| Höfling, B | 1 |
| von Arnim, T | 1 |
| Hiller, E | 1 |
| Callow, AD | 1 |
| Caplan, LR | 1 |
| Correll, JW | 1 |
| Fields, WS | 1 |
| Drück, A | 1 |
| Altenhoff, B | 1 |
| Obara, A | 1 |
| Płachta, H | 1 |
| Maruszyński, M | 1 |
| Bober, S | 1 |
| Zero, E | 1 |
| Udvardy, M | 1 |
| Török, I | 1 |
| Kaliman, J | 1 |
| Knapp, HR | 1 |
| Healy, C | 1 |
| Lawson, J | 1 |
| Goodman, DS | 1 |
| Hornstra, G | 1 |
| Sheng, FC | 1 |
| Busuttil, RW | 1 |
| Libretti, A | 1 |
| Catalano, M | 1 |
| Fujimoto, T | 1 |
| Yamazaki, H | 1 |
| Valladares, BK | 1 |
| Lemberg, L | 1 |
| Di Perri, T | 1 |
| Ninet, J | 1 |
| Bachet, P | 1 |
| Pasquier, J | 1 |
| Plate, G | 1 |
| Stanson, AW | 1 |
| Hollier, LH | 1 |
| Dewanjee, MK | 1 |
| Díez, M | 1 |
| Hamazaki, T | 1 |
| Hasunuma, K | 1 |
| Kobayashi, S | 1 |
| Shishido, H | 1 |
| Yano, S | 1 |
| Grunwald, J | 1 |
| Wood, L | 1 |
| Etherington, M | 1 |
| Jamieson, S | 1 |
| Lawford, P | 1 |
| Perlick, E | 1 |
| Brüschke, G | 1 |
| Klatt, R | 1 |
| Oehme, P | 1 |
| Boneu, B | 2 |
| Bierme, R | 2 |
| Boneu, A | 2 |
| Guiraud, B | 2 |
| Rascol, A | 1 |
| McCormick, J | 1 |
| Weily, HS | 1 |
| Steele, PP | 1 |
| Haft, JI | 1 |
| Gershengorn, K | 1 |
| Kranz, PD | 1 |
| Oestreicher, R | 1 |
| Schnetzer, GW | 1 |
| Penner, JA | 1 |
| Dziewolska, M | 1 |
| Krug, H | 1 |
| Slichter, SJ | 1 |
| Born, GV | 1 |
| Heikinheimo, R | 1 |
| Järvinen, K | 1 |
| Pris, J | 1 |
| Auvergnat, A | 1 |
| Corberand, J | 1 |
| Monnier, J | 1 |
| Besançon, F | 1 |
| Marche, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Strategies for the Prevention of Accelerated Atherosclerosis in Systemic Lupus Erythematosus - A Pilot Study[NCT00054938] | Phase 2 | 150 participants | Interventional | 2003-03-31 | Completed | ||
| Does Acetaminophen Potentiate the Gastroduodenal Mucosal Injury of Aspirin? A Prospective, Randomized, Pilot Study.[NCT00594867] | Phase 4 | 94 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV[NCT02559414] | Phase 2 | 55 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease[NCT02719665] | 30 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Arterial Imaging of Inflammation and Resolution After Endovascular Surgery[NCT03590769] | Phase 1 | 9 participants (Actual) | Interventional | 2017-06-01 | Completed | ||
| Evaluation of Diagnostic and Predictive Capabilities of Novel Application of Carotid Carotid Stenosis Pressure Gradient Measurement in Patients Undergoing Percutaneous Carotid Angioplasty and Stenting (CAS).[NCT06123767] | 200 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| [NCT00000539] | Phase 3 | 0 participants | Interventional | 1992-09-30 | Completed | ||
| Efficacy of Medifast's 5 & 1 Program Compared to a Food-based Diet After a Period of Weight Loss and Weight Maintenance[NCT01011491] | 90 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311] | Phase 4 | 70 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337] | Phase 4 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to endothelial function. (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 14.06 |
| Placebo Follow up | 13.84 |
| Aspirin Baseline | 11.18 |
| Aspirin Randomization | 12.11 |
| Clopidogrel Baseline | 13.06 |
| Clopidogrel Randomization | 12.29 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to immune activity (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 15.53 |
| Placebo Follow up | 15.43 |
| Aspirin Baseline | 13.15 |
| Aspirin Follow up | 14.96 |
| Clopidogrel Baseline | 16.03 |
| Clopidogrel Follow up | 14.85 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to inflammation (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
(NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
The primary objective of these analyses will be to compare the effects of aspirin versus control and clopidogrel versus control for the outcome of platelet activity. Aspirin is expected to decrease arachidonic acid-induced platelet aggregation by 50% versus control. Clopidogrel is expected to decrease ADP-induced platelet aggregation by 50% versus control. (NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 72.35 |
| Placebo Follow up | 79.11 |
| Aspirin Baseline | 72.79 |
| Aspirin Randomization | 26.77 |
| Clopidogrel Baseline | 71.07 |
| Clopidogrel Randomization | 65.00 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| Arm 1 of 5 Randomized Treatment Arms | 27.6 |
| Arm 2 of 5 Randomized Treatment Arms | 27.0 |
| Arm 3 of 5 Randomized Treatment Arms | 31.4 |
| Arm 4 of 5 Randomized Treatment Arms | 25.7 |
| Arm 5 of 5 Randomized Treatment Arms | 28.3 |
Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| 1 of 5 Randomized Treatment Arms | 10.0 |
| 2 of 5 Randomized Treatment Arms | 11.2 |
| 3 of 5 Randomized Treatment Arms | 10.0 |
| 4 of 5 Randomized Treatment Arms | 11.0 |
| 5 of 5 Randomized Treatment Arms | 9.6 |
135 reviews available for aspirin and Arteriosclerosis
| Article | Year |
|---|---|
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.
Topics: Anastomosis, Surgical; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Graft Occlusion, Vas | 2015 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D | 2010 |
Potential cardioprotective actions of no-releasing aspirin.
Topics: Animals; Apoptosis; Arteriosclerosis; Aspirin; Caspase Inhibitors; Cell Adhesion; Cyclic GMP; Cytoki | 2002 |
Platelets: is aspirin sufficient or must we know how to pronounce abciximab?
Topics: Abciximab; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Blood Platelets; Clopidogrel; Endarter | 2002 |
[Aspirin for primary prevention of asymptomatic atherosclerosis].
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Mid | 2002 |
Statins: the new aspirin?
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Apoptosis | 2002 |
Nonplatelet-mediated effects of aspirin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Humans; Inflammation; M | 2002 |
[Platelet inhibitors: old and new].
Topics: Abciximab; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; Dipyrid | 2002 |
High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
Topics: Arteriosclerosis; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Coronary Disease; Female; Fi | 2003 |
[Clopidogrel: background information and use in clinical practice].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinol | 2003 |
Inflammation, the metabolic syndrome and cardiovascular risk.
Topics: Arteriosclerosis; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitu | 2003 |
[Indications for anticoagulant use in secondary prevention of strokes].
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cardiovas | 2003 |
[Is the supplementation with antioxidants effective in the treatment of atherosclerosis?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antioxidants; Arteriosclerosis; A | 2004 |
Antiplatelet agents in atherothrombotic diseases.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Platelet Aggregation Inhibit | 2004 |
Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Clinical Trials as Topi | 2003 |
Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Cholest | 2004 |
Aspirin resistance in cardiovascular disease: a review.
Topics: Arteriosclerosis; Aspirin; Drug Resistance; Humans; Platelet Aggregation Inhibitors | 2004 |
Clopidogrel in the management of cerebrovascular events.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Drug Costs; Drug Therapy, Combination; Humans; Platelet Aggr | 2004 |
[Vascular dementia].
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Cyclooxygenase Inhibitors; Dementia, Vascular; F | 2004 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
[Inflammation and diabetes].
Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arte | 2004 |
Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Topics: Adenosine Diphosphate; Animals; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopidogrel; Co | 2005 |
[Mechanism and drug treatment of atherothrombosis].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; C-Reactive Protein; CD40 Antigens; Clopidogrel; Drug Ther | 2005 |
Antiplatelet agents in secondary prevention of stroke: a perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Brain Ischemia; Clinical Trials | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Antiplatelet agents and arterial thrombosis.
Topics: Age Factors; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Dose-R | 2006 |
Antiplatelet therapy in populations at high risk of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Chemoprevention; Clopidogrel; Drug Therapy, Combination; Embolism, Choles | 2006 |
[Update on antithrombotic treatments in arterial diseases].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Eptifiba | 2007 |
[Antiplatelet and anticoagulant treatment after percutaneous transluminal angioplasty for peripheral arteriosclerosis. Survey of a Cochrane review].
Topics: Angioplasty, Balloon; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Evidence-Based Medici | 2007 |
Pharmacology of platelet-affecting drugs.
Topics: Animals; Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Platelets; Cyclic AMP; Dose-Response Re | 1980 |
Platelets, prostaglandins and thrombotic disorders.
Topics: Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Platelets; Calcium; Coronary Disease; Cyclic AMP | 1981 |
[Management of transient ischemic cerebral attacks (author's transl)].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Cerebral Revascularization; Enda | 1982 |
Can drugs help patients with lower limb ischaemia?
Topics: Aged; Arteriosclerosis; Aspirin; Cholesterol; Collateral Circulation; Female; Hemodynamics; Humans; | 1982 |
Adventures and excursions in bioassay: the stepping stones to prostacyclin. Nobel Lecture, 8 December 1982.
Topics: Angiotensin I; Animals; Arteriosclerosis; Aspirin; Biological Assay; Bradykinin; Catecholamines; Cel | 1983 |
Nobel lecture, 8th December 1982. Adventures and excursions in bioassay: the stepping stones to prostacyclin.
Topics: Anaphylaxis; Animals; Arteriosclerosis; Aspirin; Biological Assay; Epoprostenol; Humans | 1983 |
Platelets, carotids, and coronaries. Critique on antithrombotic role of antiplatelet agents, exercise, and certain diets.
Topics: Angina Pectoris; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Carotid Artery Thrombosi | 1984 |
An antagonist of prostaglandin synthesis in cardiovascular diseases.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Brain Diseases; Cardiovascular Diseases; Con | 1984 |
Medical Grand Rounds: extracranial carotid artery disease.
Topics: Adolescent; Adult; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Auscultation; Carotid Art | 1980 |
Atherosclerosis and prostaglandins.
Topics: Alprostadil; Arteriosclerosis; Aspirin; Blood Vessels; Cell Membrane Permeability; Cell Survival; Ch | 1982 |
Prostacyclin.
Topics: Adenylyl Cyclases; Adult; Animals; Arteriosclerosis; Aspirin; Blood Platelet Disorders; Blood Platel | 1982 |
Platelet function in diabetes mellitus.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Diabetes Mellitus; D | 1980 |
Prostaglandins, platelets, and atherosclerosis.
Topics: Animals; Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Circulation; Blood Vessels; Carotid Art | 1980 |
Prostaglandin I2 (prostacyclin).
Topics: Animals; Arteriosclerosis; Aspirin; Blood Vessels; Cardiovascular Physiological Phenomena; Chemical | 1980 |
New strategies in the development of anti-atherosclerotic drugs.
Topics: 4-Aminobenzoic Acid; Animals; Arteriosclerosis; Aspirin; Coronary Disease; Fatty Acids, Nonesterifie | 1980 |
[Transitory cerebral ischemic attacks].
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Blood Platelets; Endarterectomy; Hemodynamics; Huma | 1981 |
Evaluation of platelet-inhibiting drugs in models of atherosclerosis.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Disease Models, Animal; Drug Eva | 1982 |
[Platelets and prostaglandins in ischemic cardiopathy. Theoretical and practical aspects and research prospects].
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Platelet Aggrega | 1982 |
Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor.
Topics: Abciximab; Amino Acid Sequence; Animals; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Disinteg | 1995 |
Surgical management of carotid artery atherosclerotic disease.
Topics: Aged; Angiography; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Cause of Death; Cerebrovascul | 1993 |
Modification of atherosclerosis by agents that do not lower cholesterol.
Topics: Animals; Antioxidants; Arteriosclerosis; Aspirin; Calcium Channel Blockers; Fibrinolytic Agents; Hep | 1993 |
When do vascular surgeons prescribe antiplatelet therapy? Current attitudes.
Topics: Angioplasty, Balloon; Arteriosclerosis; Aspirin; Dipyridamole; Graft Occlusion, Vascular; Humans; Is | 1993 |
Platelet activation mechanisms and markers in arterial thrombosis.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Hemostasis; Humans; Platelet Activation; Platel | 1996 |
Asymptomatic carotid stenosis: surgery's the answer, but that's not the question.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arteriosclerosis; Aspirin; Brain Ischemia; | 1996 |
Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study.
Topics: Age Factors; Aged; Arteriosclerosis; Aspirin; Black or African American; Coronary Disease; Dose-Resp | 1996 |
[Diagnosis and treatment of cerebrovascular accidents of cardioembolic origin].
Topics: Aged; Anticoagulants; Aortic Diseases; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cardiomyopath | 1996 |
[Preventive treatment of cerebrovascular accidents of arterial origin].
Topics: Adult; Aged; Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Clinical Trials | 1996 |
[Secondary prevention of arteriosclerosis].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Aspirin; Humans; Hypoglycemic A | 1996 |
The role of inflammation in atherosclerosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Endothelium, Vascular; | 1996 |
Plaque rupture, thrombosis, and therapeutic implications.
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Coronary Thrombosis; Disease Pr | 1996 |
Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Topics: Anti-Inflammatory Agents; Arachidonic Acid; Arteriosclerosis; Aspirin; Blood Platelets; Cyclooxygena | 1997 |
Role of transesophageal echocardiography in the management of thromboembolic stroke.
Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Aspirin; Cerebrovascular Disorde | 1997 |
Mechanism of anti-proliferative action of eicosapentaenoic acid (EPA) in vascular cell growth: its effect on signal transduction system.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Arterioscl | 1997 |
Multifactorial aspects of the treatment of the type II diabetic patient.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes | 1997 |
[Consensus antithrombotic prophylaxis of vascular incidents in patients with manifest atherosclerotic vascular diseases. Central Guidance Organization for Peer Review].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Coronary | 1998 |
The crucial, controversial carotid artery. Part II: Treatment.
Topics: Arteriosclerosis; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Humans; Ischemic Attack, Trans | 1998 |
Atherosclerosis: a unifying disorder with diverse manifestations.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine; United | 1998 |
Infectious agents in coronary artery disease: viral infection, aspirin, and gene expression in human coronary smooth muscle cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Arteriosclerosis; Aspirin; Coronary Disea | 1998 |
Effects of aspirin on endothelial dysfunction in atherosclerosis.
Topics: Acetylcholine; Animals; Arteriosclerosis; Aspirin; Drug Interactions; Endothelium, Vascular; Humans; | 1998 |
Carotid endarterectomy.
Topics: Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Pressure; Car | 1998 |
Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel.
Topics: Adenosine Diphosphate; Animals; Arteriosclerosis; Aspirin; Clopidogrel; Humans; Platelet Activation; | 1998 |
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Follow-Up Studies; Humans; Myocar | 1998 |
Rationale for the use of antiplatelet drugs in patients with peripheral vascular disease.
Topics: Arteriosclerosis; Aspirin; Clinical Trials as Topic; Disease Progression; Humans; Intermittent Claud | 1994 |
Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.
Topics: Algorithms; Arteriosclerosis; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Critic | 1999 |
[Prevention of cerebral ischemia: anti-platelet agents].
Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Humans; Intracranial Embolism; Plate | 1999 |
Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications.
Topics: Animals; Arteriosclerosis; Aspirin; Disease Progression; Endothelium, Vascular; Humans; Platelet Act | 1999 |
Heart disease. A new theory of heart attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Humans; Myocardial Infarction | 1999 |
[Antiplatelet therapy].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Clinic | 1999 |
Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; | 2000 |
[Pharmacology of aspirin].
Topics: Adult; Aged; Angina Pectoris; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Br | 2000 |
[Aspirin and antiphospholipid syndrome].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antiphospholipid Syndrome; Arteriosc | 2000 |
The role of C-reactive protein in cardiovascular disease risk.
Topics: Arteriosclerosis; Aspirin; Biomarkers; C-Reactive Protein; Coronary Disease; Female; Humans; Male; P | 1999 |
Anti-inflammatories for cardiovascular disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Cardiovascular Diseases | 2000 |
Novel platelet inhibitors.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Humans; Platelet A | 2001 |
Benefit of ADP receptor antagonists in atherothrombotic patients: new evidence.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Purinergic P2 Receptor An | 2001 |
[Secondary prevention after cardiac infarct; therapeutic efficiency--cost-benefit ratio].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Aspirin; Ca | 2001 |
[From the physiopathology of thrombosis to therapeutic targets].
Topics: Arteriosclerosis; Aspirin; Fibrinolytic Agents; Humans; Inflammation; Ischemia; Platelet Aggregation | 2001 |
C-reactive protein and cardiovascular disease: a review of risk prediction and interventions.
Topics: Age Factors; Arteriosclerosis; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Fe | 2002 |
[Acetylsalicylic acid in primary prevention of cardiovascular events; literature study].
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Diabetes Mellitus; Humans; Hyperlipidemias; Hype | 2002 |
[Do all the patients with adult-onset diabetes mellitus need acetylsalicylic acid?].
Topics: Arteriosclerosis; Aspirin; Blood Coagulation; Contraindications; Diabetes Mellitus, Type 2; Fibrinol | 1999 |
Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy.
Topics: Algorithms; Arteriosclerosis; Aspirin; Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet A | 2002 |
Efficacy and safety of aspirin in the long-term management of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Humans; Risk Assess | 2001 |
Bioactive lipids and atherothrombosis.
Topics: Animals; Arachidonic Acids; Arteriosclerosis; Aspirin; Cyclooxygenase Inhibitors; Humans; Thrombopla | 2001 |
[Prevention of recurrence in cerebral infarction].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebral Infarction; Drug Therapy, C | 2002 |
Cardiovascular risk reduction in renal transplantation. Strategies for success.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Comorbidity; Cost-Benefit | 2002 |
[Management of atherosclerotic renal artery stenoses].
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Aspirin; Cardiovascular Agents; Combined | 2002 |
Inflammation in acute coronary syndromes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Biomarkers; Cell Adhesion Molecu | 2002 |
Role of antiplatelet agents in cardioprotection.
Topics: Arteriosclerosis; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Clopidogrel; Female; Humans; | 2002 |
[Blood platelets and cardiovascular diseases. IV. Platelet-inhibiting drugs and antithrombotic agents].
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Analgesics; Anti-Inflammatory Agents; Arterioscl | 1976 |
The role of prostaglandins in platelet function.
Topics: Animals; Arteriosclerosis; Aspirin; Bleeding Time; Blood Platelets; Chemical Phenomena; Chemistry; C | 1979 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
[is there a treatment for peripheral arterial insufficiency?].
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Clofibrate; Dipyridamole; Fibrinolytic Agent | 1979 |
[Thrombangiitis obliterans: diagnosis and therapy in light of new immunological findings].
Topics: Adult; Anti-Inflammatory Agents; Antibodies; Anticoagulants; Antigen-Antibody Complex; Arteriosclero | 1979 |
Physiopathology and pharmacotherapy of occlusive arterial disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Platelets; Blood Viscosity; Cerebrovas | 1979 |
The pathophysiology of transient cerebral ischemic attacks.
Topics: Arteriosclerosis; Aspirin; Carotid Arteries; Cerebrovascular Disorders; Cholesterol; Embolism; Endoc | 1979 |
Platelet-endothelial cell interactions.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Complement System Proteins; Endo | 1979 |
[Transient ischemia attacks in general practice].
Topics: Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Carotid Arteries; Diagnosis, | 1979 |
[Prophylactic value of platelet anti-aggregants in coronary disease].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Embolism; Hea | 1979 |
[Prospects of antiaggregant therapy in prevention of atherosclerosis].
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Arteriosclerosis; Aspirin; Blood Coagulation Diso | 1979 |
Prostaglandins in circulatory disorders.
Topics: Angiotensin II; Antihypertensive Agents; Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Platele | 1979 |
[Transient cerebral ischemia--etiology and management].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Female; Humans; Hypotension; Intracranial Embolism and Th | 1976 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Transient cerebral ischemic attacks.
Topics: Anticoagulants; Arrhythmias, Cardiac; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blindn | 1976 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
The porcine model for the understanding of thrombogenesis and atherogenesis.
Topics: Angioplasty, Balloon, Coronary; Animals; Aorta; Aortic Diseases; Arteriosclerosis; Aspirin; Coronary | 1991 |
Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly.
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Fem | 1991 |
Carotid artery disease: when and how to treat?
Topics: Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Hum | 1991 |
Atherosclerotic carotid disease and the eye.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blindness; Carotid Artery Diseas | 1991 |
Acetylsalicylic acid and the balance between prostacyclin and thromboxane A2.
Topics: Arteriosclerosis; Aspirin; Clinical Trials as Topic; Drug Administration Schedule; Epoprostenol; Fem | 1990 |
[Platelet aggregation, coronary insufficiency and aspirin].
Topics: Arteriosclerosis; Aspirin; Drug Administration Schedule; Heart Failure; Humans; Myocardial Infarctio | 1990 |
Pathological significance of the thromboxane-prostacyclin hypothesis.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Epoprostenol; Humans; Prostaglan | 1985 |
The Jeremiah Metzger lecture. Participation of eicosanoids in the syndromes of myocardial ischemia.
Topics: Angina, Unstable; Arteriosclerosis; Aspirin; Coronary Disease; Eicosanoids; Humans; Myocardial Infar | 1990 |
[Anticoagulants and inhibitors of thrombocyte function in the long-term treatment of arteriosclerosis].
Topics: Adult; Anticoagulants; Arteriosclerosis; Aspirin; Dose-Response Relationship, Drug; Humans; Middle A | 1989 |
[Platelet antiaggregants in cerebral ischemic pathology].
Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Humans; Platelet Aggregation Inhibit | 1989 |
Platelets and prostaglandins in sudden death: therapeutic implications.
Topics: Adrenergic beta-Antagonists; Animals; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis; Aspirin | 1985 |
Platelets and antiplatelet therapy in ischemic heart disease.
Topics: Angina Pectoris; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials a | 1986 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets | 1986 |
Coronary artery bypass grafting. A model for the understanding of the progression of atherosclerotic disease and the role of pharmacological intervention.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Collagen; Coronary Artery Bypass | 1985 |
The role of arachidonic acid metabolites in cardiovascular homeostasis. Biochemical, histological and clinical cardiovascular effects of non-steroidal anti-inflammatory drugs and their interactions with cardiovascular drugs.
Topics: Arteriosclerosis; Aspirin; Coronary Disease; Eicosanoic Acids; Heart Valve Prosthesis; Homeostasis; | 1987 |
The role of platelets in the development and complications of atherosclerosis.
Topics: Animals; Antigen-Antibody Complex; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Comple | 1986 |
Carotid surgery in stroke prevention.
Topics: Aged; Arteriosclerosis; Aspirin; Blindness; Carotid Arteries; Carotid Artery Diseases; Cerebrovascul | 1986 |
[Thrombosis in various diseases: arteriosclerosis and thrombosis].
Topics: Animals; Arteriosclerosis; Aspirin; Dipyridamole; Humans; Sulfinpyrazone; Thrombosis | 1986 |
[The fate of patients with carotid stenosis. Comparative study, based on the literature, of their natural history and evolution under medical treatment or following endarterectomy].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Brain Ischemia; Carotid Artery Diseases; Combined Modalit | 1985 |
Prostacyclin, from discovery to clinical application.
Topics: Animals; Arteriosclerosis; Aspirin; Cell Survival; Disease; Epoprostenol; Extracorporeal Circulation | 1985 |
Platelets, thrombosis and coronary artery disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Blood Protein Disorders; Cell Survival; Coronary Disease | 1973 |
Platelet pharmacology in relation to thrombosis.
Topics: Adenine Nucleotides; Animals; Arteriosclerosis; Aspirin; Binding Sites; Blood Cells; Blood Coagulati | 1970 |
58 trials available for aspirin and Arteriosclerosis
| Article | Year |
|---|---|
Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel.
Topics: Aged; Arteriosclerosis; Aspirin; Blood Platelets; Brain Ischemia; C-Reactive Protein; Clopidogrel; D | 2002 |
Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inh | 2004 |
The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease.
Topics: Adenosine Diphosphate; Aged; Arteriosclerosis; Aspirin; Blood Platelets; Cell Shape; Clopidogrel; Dr | 2004 |
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; | 2004 |
Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) Study.
Topics: Administration, Oral; Aged; Anticoagulants; Arteriosclerosis; Aspirin; Female; Fibrinolytic Agents; | 2005 |
Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Aspirin; Drug Therapy, Combinat | 2005 |
Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke.
Topics: Adult; Arteriosclerosis; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; C-Reactive Protein; C | 2006 |
[Controlled cooperative trial of secondary prevention of cerebral ischemic accidents caused by atherosclerosis, using aspirin and dipyridamole].
Topics: Aged; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; | 1983 |
[Role of antiplatelet agents in the prevention of cerebral ischemic accidents].
Topics: Adult; Aged; Anticoagulants; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials as Topic; C | 1983 |
Platelets and prostaglandins in coronary artery disease. Rationale for use of platelet-suppressive drugs.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Dip | 1983 |
Medical Grand Rounds: extracranial carotid artery disease.
Topics: Adolescent; Adult; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Auscultation; Carotid Art | 1980 |
The factor VIII complex in atherosclerosis: effects of aspirin.
Topics: Adult; Aged; Antigens; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Factor VIII; Female; Hum | 1981 |
Series on pharmacology in practice. 10. Antithrombotic therapy: role of platelet-inhibitor drugs. III. Management of arterial thromboembolic and atherosclerotic disease (third of three parts).
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1981 |
A comparative evaluation of externally supported polytetrafluoroethylene axillobifemoral and axillounifemoral bypass grafts.
Topics: Aged; Aged, 80 and over; Anastomosis, Surgical; Aorta; Arteriosclerosis; Aspirin; Axillary Artery; B | 1995 |
Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease.
Topics: Aged; Antithrombin III; Arteriosclerosis; Aspirin; Bleeding Time; Coronary Artery Bypass; Coronary D | 1995 |
Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study.
Topics: Age Factors; Aged; Arteriosclerosis; Aspirin; Black or African American; Coronary Disease; Dose-Resp | 1996 |
Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results.
Topics: Arteriosclerosis; Aspirin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Res | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. ACAS Investigators. Asymptomatic Carotid Atherosclerosis Study.
Topics: Anesthesia; Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebral Infarction; Combined Modality Ther | 1996 |
[Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors].
Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Dose-Response Re | 1996 |
[Recent antithrombotic gold standard?].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Thrombosis; Ticlopi | 1997 |
Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.
Topics: Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Case-Control Studies; Double-Blind Method; H | 1998 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Aspirin improves endothelial dysfunction in atherosclerosis.
Topics: Acetylcholine; Arteriosclerosis; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Endothelium, Va | 1998 |
Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography.
Topics: Aged; Anticoagulants; Aortic Diseases; Arteriosclerosis; Aspirin; Atrial Fibrillation; Drug Therapy, | 1998 |
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Follow-Up Studies; Humans; Myocar | 1998 |
Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography.
Topics: Aged; Anticoagulants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Aspirin; Atrial Fibrillati | 1999 |
Effects of triflusal on arteriosclerosis progression assessed with high-resolution arterial ultrasound.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Arteriosclerosis; Aspirin; Carotid Artery D | 1999 |
Comparison of antiplatelet activity of microencapsulated aspirin 162.5 Mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Capsules; Delayed-Action Preparations; Female; Humans; M | 1999 |
Intravenous acetylsalicylic acid, magnesium and their combination in experimental arterial thrombosis in rats.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Pressure; Double-Blind Method; Hemorrhage; Magnesium; Male | 1999 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest | 1999 |
[ASS or clopidogrel? In high vascular risk it is best to give both].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhi | 2000 |
Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis | 2000 |
Effect of contralateral occlusion on long-term efficacy of endarterectomy in the asymptomatic carotid atherosclerosis study (ACAS). ACAS Investigators.
Topics: Aged; Arteriosclerosis; Aspirin; Carotid Stenosis; Disease-Free Survival; Endarterectomy, Carotid; F | 2000 |
Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease.
Topics: Aged; Anticholesteremic Agents; Anticoagulants; Antioxidants; Arteriosclerosis; Aspirin; Cholesterol | 2000 |
Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
Topics: Aged; Arteriosclerosis; Aspirin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Fi | 2001 |
[Blood rheological disorders in atherosclerotic lesion of the abdominal aorta and their correction by the use of aspirin].
Topics: Adult; Aged; Aorta, Abdominal; Aortic Diseases; Arteriosclerosis; Aspirin; Blood Circulation; Clinic | 1979 |
[Disorder of the rheological properties of the blood as a risk factor in interventions on the abdominal aorta and its branches].
Topics: Adult; Aged; Aorta, Abdominal; Aortic Aneurysm; Arteriosclerosis; Aspirin; Blood Cell Count; Blood V | 1979 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Anti-aggregants in clinical practice.
Topics: Arteriosclerosis; Aspirin; Clinical Trials as Topic; Embolism; Humans; Platelet Aggregation; Thrombo | 1975 |
[Use of acetylsalicylic acid in the prevention of re-occlusion following revascularization interventions. Results of a double-blind long term study].
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Double-Blind Method; Female; Follow-Up Studi | 1977 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
Indobufen versus dipyridamole plus aspirin in the treatment of patients with peripheral atherosclerotic disease.
Topics: Aged; Arteriosclerosis; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Humans; Isoindoles | 1992 |
Effects of aspirin, dipyridamole, nifedipine and cavinton which act on platelet aggregation induced by different aggregating agents alone and in combination.
Topics: Adenosine Diphosphate; Arteriosclerosis; Aspirin; Collagen; Dipyridamole; Double-Blind Method; Epine | 1992 |
Asymptomatic carotid atherosclerosis study: role of the clinical coordinator.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Combined Modali | 1992 |
Arterial response to ketanserin and aspirin in patients with advanced peripheral atherosclerosis.
Topics: Adult; Aged; Aged, 80 and over; Arteries; Arteriosclerosis; Aspirin; Female; Humans; Ketanserin; Mal | 1992 |
Dose-dependent aspirin hydrolysis and platelet aggregation in patients with atherosclerosis.
Topics: Adenosine Diphosphate; Arteriosclerosis; Aspirin; Collagen; Dose-Response Relationship, Drug; Double | 1992 |
Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly.
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Fem | 1991 |
Stenosis following laser thermal angioplasty--a blinded controlled randomized study between aspirin against Probucol.
Topics: Angioplasty, Laser; Animals; Aorta; Arteriosclerosis; Aspirin; Constriction, Pathologic; Female; Hot | 1991 |
[Research on the critical dose for antithrombotic effectiveness of aspirin in the Chinese].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Double-Blind Method; Female; | 1990 |
Platelets and antiplatelet therapy in ischemic heart disease.
Topics: Angina Pectoris; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials a | 1986 |
Thromboxane receptor blockade versus cyclooxigenase inhibition: antiplatelet effects in patients.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angioplasty, Balloon; Arterioscl | 1986 |
Carotid endarterectomy: what is its current status?
Topics: Arteriosclerosis; Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders; Cli | 1988 |
[Evaluation of the effect of polopirin S on platelet adhesiveness in chronic peripheral circulatory failure in arteriosclerosis].
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Chronic Disease; Clinical Trials as Topic; Humans; Ischemia; | 1988 |
Diminished platelet residence time on active human atherosclerotic lesions in-vivo--evidence for an optimal dose of aspirin?
Topics: Administration, Oral; Aged; Arteriosclerosis; Aspirin; Blood Platelets; Dose-Response Relationship, | 1988 |
Treatment of claudication with dipyridamole and aspirin.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combin | 1986 |
Aspirin in prophylaxis of ischemic heart disease.
Topics: Arteriosclerosis; Aspirin; Clinical Trials as Topic; Coronary Disease; Humans; Platelet Adhesiveness | 1973 |
Acetylsalicylic acid and arteriosclerotic-thromboembolic diseases in the aged.
Topics: Aged; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Morbidity; Placebos | 1971 |
202 other studies available for aspirin and Arteriosclerosis
| Article | Year |
|---|---|
Biological significance and therapeutic potential of prostacyclin.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Coagulation; Blood Platelets; Epoprostenol; Humans; Lipid | 1980 |
2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities.
Topics: Animals; Arteriosclerosis; Cilostazol; Hyperplasia; Platelet Aggregation Inhibitors; Quinolines; Qui | 1998 |
Reversible cerebral vasoconstriction complicating cerebral atherosclerotic vascular disease in Schimke immuno-osseous dysplasia.
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Carvedilol; Child; Clopidogrel; Diagnosis, Differential; | 2018 |
[Secondary prevention: is arteriosclerosis already an illness?].
Topics: Arteriosclerosis; Aspirin; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito | 2013 |
Acetylsalicylic acid (ASA) - How much, how often, and when? A clinical-pharmacological perspective.
Topics: Arteriosclerosis; Aspirin; Dose-Response Relationship, Drug; Hemostatics; Humans; Pharmacology, Clin | 2016 |
[Thrombocyte aggregation inhibitor after surgery for an abdominal aortic aneurysm].
Topics: Aortic Aneurysm, Abdominal; Arteriosclerosis; Aspirin; Blood Vessel Prosthesis Implantation; Cardiov | 2008 |
Using icon arrays to communicate medical risks: overcoming low numeracy.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Aspirin; Attitude to Health; Computer Graph | 2009 |
New daily aspirin guidelines address age, sex differences.
Topics: Adult; Age Factors; Aged; Arteriosclerosis; Aspirin; Female; Humans; Male; Middle Aged; Platelet Agg | 2009 |
Antiplatelet therapy: aspirin for asymptomatic atherosclerosis?
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Risk; R | 2010 |
Low-dose aspirin-induced gastroduodenal mucosal injury in Japanese patients with arteriosclerotic disease.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Asian People; Aspirin; Female; Histamine H2 Antago | 2010 |
Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases.
Topics: Arteriosclerosis; Aspirin; Cerebral Infarction; Coronary Disease; Female; Humans; Hypolipidemic Agen | 2002 |
Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Arteriosclerosis; Aspirin; Culture Techniqu | 2002 |
Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Aspirin; Foam Cells; Hypercholesterolemia; Lipoproteins, | 2002 |
Ask the doctor. I have atherosclerosis in the arteries of my heart and neck, and my doctors want me to take aspirin. I also have arthritis and take Naprosyn for it every day. I have heard that Naprosyn can prevent blood clots, just like aspirin does. Can
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Coronary Vessels; Drug Therapy, | 2002 |
[Effect of fluvastain and its combination with aspirin and trental on hemostasis and microcirculation in atherosclerosis].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Aspirin; Drug Therapy, Combination; Fatty A | 2002 |
Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects.
Topics: Adenosine Diphosphate; Analysis of Variance; Arachidonic Acid; Arteriosclerosis; Aspirin; Blood Gluc | 2003 |
Inflammation in atherosclerosis: causal or casual? The need for randomized trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Humans; Inflammation; Randomized | 2003 |
[Effect of aspirin combined with perindopril on prostacyclin, thromboxone A2, and norepinephrine in the blood of arteriosclerosis rabbit models and the cardiac function].
Topics: Animals; Arteriosclerosis; Aspirin; Drug Synergism; Epoprostenol; Female; Heart Function Tests; Hear | 2003 |
CAUSAL INFLUENCES IN HAEMATEMESIS AND MELAENA.
Topics: Alcoholic Beverages; Arteriosclerosis; Aspirin; Blood Group Antigens; Duodenal Ulcer; Genetics, Medi | 1965 |
[Platelets and arterial thrombosis].
Topics: Adenosine Diphosphate; Angioplasty, Balloon; Anti-Bacterial Agents; Arterial Occlusive Diseases; Art | 2003 |
A case of frequently recurring amaurosis fugax with atherothrombotic ophthalmic artery occlusion.
Topics: Amaurosis Fugax; Angiography, Digital Subtraction; Arterial Occlusive Diseases; Arteriosclerosis; As | 2004 |
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Topics: Aged; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Databases, Factual; Female; Hospitaliz | 2004 |
[Is aspirin resistance a reality?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Drug Interactions; Drug Resistan | 2004 |
[Migraine, inflammation, genes. New risk factors for stroke].
Topics: Adult; Arteriosclerosis; Aspirin; C-Reactive Protein; Case-Control Studies; Contraceptives, Oral; Fe | 2003 |
Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Arteries; Disease | 2004 |
Aspirin inhibits monocyte chemoattractant protein-1 and interleukin-8 expression in TNF-alpha stimulated human umbilical vein endothelial cells.
Topics: Animals; Arteriosclerosis; Aspirin; Cell Adhesion; Cell Movement; Cells, Cultured; Chemokine CCL2; E | 2004 |
Aspirin attenuates the initiation but not the progression of atherosclerosis in apolipoprotein E-deficient mice fed a high-fat, high-cholesterol diet.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Apolipoproteins E; Arterioscleros | 2004 |
Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Cells, Cultured; Chelat | 2004 |
There is no evidence that the benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Pro | 2004 |
Mixed connective tissue disease associated with antineutrophil cytoplasmic antibodies against proteinase-3 and systemic atherosclerosis: a case report.
Topics: Antibodies, Antineutrophil Cytoplasmic; Arteriosclerosis; Aspirin; Autoantibodies; Cholesterol, LDL; | 2004 |
[Attack on many vascular fronts. Atherothrombosis trouble seldom comes alone].
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2004 |
[Secondary prevention after ischemic stroke. High risk patients need special protection].
Topics: Arteriosclerosis; Aspirin; Cerebral Infarction; Clinical Trials as Topic; Clopidogrel; Humans; Intra | 2004 |
Clinical and angiographic outcome after interventional treatment of the iliac arteries with a new carbofilm coated stent: preliminary results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiography; Anticoagulants; Arterial Occlusive Disea | 2004 |
Effects of acetylsalicylic acid on experimental atherogenesis induced in rabbits.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Diet, Atherogenic; Male | 2004 |
Long-term combination therapy with aspirin and clopidogrel.
Topics: Angina, Unstable; Arteriosclerosis; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Double-Blind Me | 2004 |
Emerging therapies: clopidogrel and aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopid | 2005 |
Clinical characteristics of patients with ischemic ocular nerve palsies and lacunar brain infarcts: a retrospective comparative study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Brain I | 2005 |
Cardiovascular risk in patients with type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Aspirin; Ca | 2005 |
Large paraspinal and iliopsoas muscle hematomas.
Topics: Accidental Falls; Anticoagulants; Arteriosclerosis; Aspirin; Electromyography; Hematoma; Heparin; Hu | 2005 |
Lack of significant effect of low doses of aspirin on the concentrations of C-reactive protein in a group of individuals with atherothrombotic risk factors and vascular events.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Biomarkers; C-Reactive Pr | 2006 |
[The clinical use of aspirin in patients with atherosclerotic cardiovascular disease: 2005 Chinese Expert Consensus Document].
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Humans; Professional Staff Committees | 2006 |
[More modest use in secondary prevention, risky in primary prevention].
Topics: Arteriosclerosis; Aspirin; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Double-Bli | 2006 |
[Clopidogrel and aspirin versus aspirin alone in prevention of atherothrombotic events. The results of CHARISMA study].
Topics: Aged; Arteriosclerosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middl | 2006 |
Antithrombotic therapy and predilection for cerebellar hemorrhage.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arteriosclerosis; Aspirin; Blo | 2007 |
Update on the use of antiplatelet agents in secondary stroke prevention.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Embolism, Cholester | 2007 |
Effects of 11-week increases in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggregation.
Topics: Adult; Arteriosclerosis; Aspirin; Bleeding Time; Blood Platelets; Diet; Eicosanoic Acids; Eicosapent | 1981 |
[Inhibitors of thrombocytic function for prophylaxis of coronary heart disease (author's transl)].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anticoagulants; Arteriosclerosis; Aspirin; Coronary Diseas | 1982 |
Pharmacology of angioplasty and intravascular thrombolysis.
Topics: Angioplasty, Balloon; Anticoagulants; Arteriosclerosis; Aspirin; Blood Platelets; Dextrans; Dipyrida | 1982 |
[A method of determining the antiaggregation activity of the vascular wall in man].
Topics: Arteriosclerosis; Aspirin; Blood Vessels; Breast Neoplasms; Endothelium; Epoprostenol; Humans; Plate | 1983 |
Heritable alpha 2-macroglobulin deficiency in a patient with arterial thrombosis: alpha 2-macroglobulin deficiency Irvine.
Topics: alpha-Macroglobulins; Arteriosclerosis; Aspirin; Dipyridamole; Female; Gangrene; Humans; Immunoelect | 1984 |
[Changes in mucopolysaccharides and ultrastructural alterations in experimental atheromatosis].
Topics: Animals; Aorta; Arteriosclerosis; Aspirin; Diet, Atherogenic; Dipyridamole; Endothelium; Fibrinolyti | 1982 |
Aspirin inhibition of platelet deposition at angioplasty sites: demonstration by platelet scintigraphy.
Topics: Adult; Aged; Angioplasty, Balloon; Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Humans; Ind | 1984 |
[Therapy of peripheral arterial occlusive diseases. Round table conference].
Topics: Alprostadil; Angioplasty, Balloon; Anti-Bacterial Agents; Anticoagulants; Arterial Occlusive Disease | 1983 |
Effect of antiplatelet therapy on restenosis after experimental angioplasty.
Topics: Angioplasty, Balloon; Animals; Arteriosclerosis; Aspirin; Blood Platelets; Dipyridamole; Iliac Arter | 1984 |
Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients.
Topics: Administration, Oral; Aged; Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Cul | 1983 |
[Evaluation of the effects of plafibride and lysine acetyl salicylate on the production of PGI2].
Topics: Animals; Aorta; Arteriosclerosis; Aspirin; Clofibrate; Clofibric Acid; Diet, Atherogenic; Epoprosten | 1983 |
[The effect of ticlopidine and lysine acetylsalicylate on fibrinolytic activity of the arterial wall in experimental atherosclerosis].
Topics: Animals; Arteriosclerosis; Aspirin; Fibrinolysis; Lysine; Male; Muscle, Smooth, Vascular; Rabbits; T | 1984 |
[Aspirin and dipyridamol or preventive diet].
Topics: Arteriosclerosis; Aspirin; Dietary Fats; Dipyridamole; Humans; Platelet Aggregation; Prostanoic Acid | 1984 |
Effect of prolonged treatment with acetylsalicylic acid and dipyridamole on platelet thromboxane A2 production in atherosclerotic subjects.
Topics: Aged; Arteriosclerosis; Aspirin; Blood Platelets; Dipyridamole; Female; Humans; Kinetics; Male; Thro | 1983 |
[Preventive medical treatment of cerebral ischemic accidents related to atherosclerosis].
Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Female; Humans; Hypertension; Male; Middle Aged; Platelet | 1984 |
Etiologic factors for recurrent carotid artery stenosis.
Topics: Anesthesia; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Constriction, Pathologic; Coronary D | 1983 |
Aspirin therapy for thromboembolic disease.
Topics: Arteriosclerosis; Aspirin; Humans; Thromboembolism | 1983 |
Anti-proliferative effect of pyridinolcarbamate and of aspirin in the early stages of atherogenesis in swine.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Aspirin; Carbamates; Cholesterol; Coronary Vessels; Die | 1983 |
Non-steroidal anti-inflammatory agents and coronary heart disease.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Caroti | 1980 |
Significance of platelet function and thromboxane B2 levels across the human myocardial vascular bed.
Topics: Arteriosclerosis; Aspirin; Coronary Circulation; Coronary Disease; Coronary Vessels; Dipyridamole; H | 1981 |
Arachidonic acid metabolites, hypertension and arteriosclerosis.
Topics: Arachidonic Acids; Arteriosclerosis; Aspirin; Dinoprostone; Humans; Hypertension; Platelet Adhesiven | 1982 |
Prevention of lipid accumulation in experimental vein bypass grafts by antiplatelet therapy.
Topics: Animals; Arteriosclerosis; Aspirin; Coronary Artery Bypass; Dipyridamole; Hyperlipidemias; Lipid Met | 1982 |
Atherosclerosis in diabetes mellitus.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Diabetes Complications; Diabetes Mellitus; Epoprostenol; | 1981 |
[The role of prostacycline, thromboxane A2 and prostaglandins in platelet aggregation (author's transl)].
Topics: Arteriosclerosis; Aspirin; Epoprostenol; Hemostasis; Platelet Aggregation; Prostaglandin Antagonists | 1981 |
Antiplatelet therapy.
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprost | 1981 |
Platelets and coronary heart disease: therapy update.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprostenol; Hemostasis | 1982 |
Comparison of the effects of aspirin and indomethacin on aortic atherogenesis induced in rabbits.
Topics: Animals; Aorta; Arteriosclerosis; Aspirin; Blood Coagulation; Cholesterol; Diet, Atherogenic; Indome | 1982 |
[Anti-platelet aggregation therapy and ischaemic cerebral accidents due to atheroma (author's transl)].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Brain Ischemia; Humans; Platelet Aggregation | 1982 |
Dietary and pharmacologic control of atherosclerosis regression in cynomolgus macaques (Macaca fascicularis).
Topics: Animals; Antihypertensive Agents; Aorta; Arteriosclerosis; Aspirin; Cholesterol; Cholesterol, Dietar | 1981 |
[Aspirin sensitivity of healthy persons and patients].
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Coronary Disease; Drug Resistance; Female; Humans; Male; Mid | 1981 |
[Acetylsalicylic acid and the procoagulant activity of erythrocytes].
Topics: Adult; Anticoagulants; Arteriosclerosis; Aspirin; Blood Coagulation; Cells, Cultured; Erythrocytes; | 1981 |
Congenital deficiency of cyclo-oxygenase in a woman with generalized atherosclerosis.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Female; Humans; Middle Aged; Oxygenases; Platelet Aggreg | 1981 |
The effect of low-dose aspirin and dipyridamole upon atherosclerosis in the rabbit.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Aspirin; Dipyridamole; Drug Therapy, Combination; Female | 1981 |
The effect of acetylsalicylic acid (ASA) on the development of atherosclerotic lesions in miniature swine.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Aspirin; Cholesterol; Collagen; Male; Swine | 1980 |
[Indications for surgical treatment and medical treatment of atherosclerosis].
Topics: Arteriosclerosis; Aspirin; Cholestyramine Resin; Clofibrate; Dextrothyroxine; Dipyridamole; Humans; | 1980 |
Operative indication in asymptomatic carotid arterial disease.
Topics: Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Gui | 1995 |
Inhibition of restenosis by beraprost sodium (a prostaglandin I2 analogue) in the atherosclerotic rabbit artery after angioplasty.
Topics: Administration, Oral; Angioplasty, Balloon; Animals; Arteriosclerosis; Aspirin; Cholesterol, Dietary | 1995 |
Epidemiological feasibility of cardiovascular primary prevention in general practice: a trial of vitamin E and aspirin. Collaborative group of the Primary Prevention Project.
Topics: Aged; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clinical Protocols; Contraindications; Dia | 1995 |
What effect does controlling platelets have on atherosclerosis?
Topics: Adenylyl Cyclases; Animals; Arteriosclerosis; Aspirin; Blood Platelets; Calcium; Capillary Permeabil | 1995 |
Effect of inhibitors of factor Xa or platelet adhesion, heparin, and aspirin on platelet deposition in an atherosclerotic rabbit model of angioplasty injury.
Topics: Angioplasty, Balloon, Coronary; Animals; Arteriosclerosis; Arthropod Proteins; Aspirin; Blood Platel | 1995 |
Lord Moran's prescriptions for Churchill.
Topics: Amphetamines; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Famous Persons; History, 20th Ce | 1995 |
[Atherosclerosis also caused by local vascular inflammation].
Topics: Arteriosclerosis; Aspirin; Dose-Response Relationship, Drug; Humans | 1994 |
Risk factors for carotid atherosclerosis and platelet activation.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Fem | 1994 |
[Atherosclerosis also caused by local vascular inflammation].
Topics: Arteriosclerosis; Aspirin; Endothelium, Vascular; Humans; Inflammation | 1994 |
Aspirin inhibits platelet activity but does not attenuate experimental atherosclerosis.
Topics: Analysis of Variance; Angioplasty, Balloon; Animals; Aorta; Arteriosclerosis; Aspirin; Bleeding Time | 1993 |
A personal view: the Asymptomatic Carotid Atherosclerosis Study results--read the label carefully.
Topics: Arteriosclerosis; Aspirin; Canada; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Caro | 1996 |
Low-dose aspirin does not attenuate platelet aggregation or atherosclerosis in miniature swine but decreases production of aortic wall prostacyclin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Arteriosclerosis; Aspirin; Azo Compounds; Coloring Age | 1995 |
Postischemic hyperemia in subjects with lower limbs obstructive arteriopathy: role of PGI2 and endothelin.
Topics: Aged; Arteriosclerosis; Aspirin; Endothelins; Epoprostenol; Hemodynamics; Humans; Hyperemia; Ilopros | 1997 |
Acetylsalicylic acid and vitamin E in prevention of arterial thrombosis.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Drug Interactions; Humans; Myocardial Infarcti | 1997 |
Mobile thromboses of the aortic arch without aortic debris. A transesophageal echocardiographic finding associated with unexplained arterial embolism. The Filiale Echocardiographie de la Société Française de Cardiologie.
Topics: Adult; Aorta, Thoracic; Arteriosclerosis; Aspirin; Blood Coagulation Tests; Diabetes Complications; | 1997 |
Both dietary fish-oil supplementation and aspirin fail to inhibit atherosclerosis in long-term vein bypass grafts in moderately hypercholesterolemic nonhuman primates.
Topics: Animals; Arteriosclerosis; Aspirin; Coronary Artery Bypass; Dietary Fats, Unsaturated; Drug Synergis | 1997 |
Clopidogrel: a new safe and effective antiplatelet agent. But unanswered questions remain.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Pl | 1997 |
XIX congress of the European Society of Cardiology August 24-28, 1997, Stockholm, Sweden.
Topics: Amiodarone; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Anticoagulants; Arteriosclerosis | 1997 |
Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease.
Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Humans; Myocardial Infa | 1998 |
[Consensus on antithrombotic prophylaxis of vascular events in patients with manifested atherosclerotic vascular disease].
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Cou | 1998 |
Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Coronary Disease; Cross-Sectional Studies; Female; Humans; H | 1998 |
Decreased prevalence of symptomatic atherosclerosis in arthritis patients on long-term aspirin therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Arthritis | 1998 |
Shifting paradigms of antiplatelet therapy: assessing new drugs versus old. Introduction.
Topics: Arteriosclerosis; Aspirin; Chemistry, Pharmaceutical; Clopidogrel; Humans; Platelet Aggregation Inhi | 1998 |
Salicylate promotes myeloperoxidase-initiated LDL oxidation: antagonization by its metabolite gentisic acid.
Topics: Arteriosclerosis; Aspirin; Free Radical Scavengers; Free Radicals; Gentisates; Humans; Hydroxybenzoa | 1999 |
Oxidation of LDL and extent of peripheral atherosclerosis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Arteriosclerosis; Aspirin; Cholest | 1999 |
The Canadian Study of Cardiac Transplantation. Atherosclerosis. Investigators of the CASCADE Study.
Topics: Adult; Antihypertensive Agents; Arteriosclerosis; Aspirin; Cardiovascular Agents; Cyclosporine; Cyto | 1999 |
[The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
Topics: Aged; Arteriosclerosis; Aspirin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Fi | 1999 |
Cyclooxygenase-2 regulates granulocyte-macrophage colony-stimulating factor, but not interleukin-8, production by human vascular cells: role of cAMP.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Arteriosclerosis; Aspirin; Bucladesi | 2000 |
The salicylate metabolite gentisic acid, but not the parent drug, inhibits glucose autoxidation-mediated atherogenic modification of low density lipoprotein.
Topics: Arteriosclerosis; Aspirin; Cells, Cultured; Diabetic Angiopathies; Endothelium, Vascular; Gentisates | 2000 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
[Creative mathematics with clopidogrel; exaggeration of the preventive effect by the pharmaceutical company].
Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clopidogrel; Data I | 2000 |
The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aorta; Apolipoproteins | 2000 |
Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity.
Topics: Aged; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Aspirin; Carotid Arteries; Carotid Artery | 2000 |
Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries.
Topics: Arteriosclerosis; Aspirin; Biopsy; Carotid Artery Diseases; Case-Control Studies; Cyclooxygenase 1; | 2000 |
Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis.
Topics: Age Factors; Animals; Aorta; Arteriosclerosis; Aspirin; Diet, Atherogenic; Disease Models, Animal; E | 2000 |
The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Aspirin; Body Weight; Iron; Lipids; Lipoproteins; Mice | 2000 |
Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis.
Topics: Aged; Arteriosclerosis; Ascorbic Acid; Aspirin; C-Reactive Protein; Female; Fibrinogen; Humans; Hype | 2001 |
Blood polymorphonuclear leukocyte activation in atherosclerosis: effects of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Case-Control Studies; Chemotaxis | 2001 |
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; D | 2001 |
Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis--the influence of aspirin and cigarette smoking.
Topics: Adenosine Diphosphate; Adult; Aged; Arteriosclerosis; Aspirin; beta-Thromboglobulin; Biomarkers; Cho | 2001 |
Preventing atherosclerotic events with aspirin.
Topics: Arteriosclerosis; Aspirin; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet Aggregati | 2002 |
Efficacy and safety of aspirin in the long-term management of atherothrombosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Platelets; Cardiovascular | 2002 |
Use of oral antithrombotic agents among health maintenance organization members with atherosclerotic cardiovascular disease.
Topics: Administration, Oral; Aged; Arteriosclerosis; Aspirin; Comorbidity; Coronary Artery Disease; Drug Ut | 2002 |
Reduced tissue factor pathway inhibitor-1 after pharmacological thrombolysis: an epiphenomenon or potential culprit in rethrombosis?
Topics: Animals; Anticoagulants; Arteriosclerosis; Aspirin; Fibrinolytic Agents; Heparin; Humans; Lipoprotei | 2002 |
Atherosclerosis: the new view.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Arterie | 2002 |
[Arteriosclerosis and thrombocyte aggregation].
Topics: Adrenergic beta-Antagonists; Arteriosclerosis; Aspirin; Humans; Myocardial Infarction; Platelet Aggr | 1977 |
[Prevention of cardiovascular complications in manifest arteriosclerosis by the use of Micristine].
Topics: Adenosine Diphosphate; Anticoagulants; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Humans; P | 1979 |
Aspirin inhibits development of coronary atherosclerosis in cynomolgus monkeys (Macaca fascicularis) fed an atherogenic diet.
Topics: Animals; Aortic Diseases; Arteriosclerosis; Aspirin; Coronary Disease; Diet, Atherogenic; Haplorhini | 1979 |
Studies on the progression and regression of coronary and peripheral atherosclerosis in the cynomolgus monkey. I. Effects of dipyridamole and aspirin.
Topics: Animals; Aorta; Arteries; Arteriosclerosis; Aspirin; Calcium; Cholesterol; Cholesterol, Dietary; Col | 1979 |
Effect of risk factors and antirheumatic drugs on the proliferation of aortic wall cells.
Topics: Animals; Aorta; Arteriosclerosis; Aspirin; Cell Division; Cells, Cultured; Chloroquine; Diabetes Mel | 1979 |
Does aspirin have a prophylactic vascular effect?
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Hum | 1979 |
Dietary PUFAs, lipid peroxides, atherosclerosis, aspirin.
Topics: Animals; Arteriosclerosis; Aspirin; Cats; Dietary Fats; Fatty Acids, Unsaturated; Humans; Lipid Pero | 1979 |
[Arteriosclerosis and thrombosis, new pathogenetic viewpoints].
Topics: Arteriosclerosis; Aspirin; Blood Circulation; Endothelium; Epoprostenol; Factor VIII; Humans; Thromb | 1978 |
Anti-inflammatory drugs in experimental atherosclerosis. Part 4. Inhibition of atherosclerosis in vivo and thromboxane synthesis and platelet aggregation in vitro.
Topics: Aminopyrine; Animals; Anti-Inflammatory Agents; Arteriosclerosis; Aspirin; Drug Evaluation; Flufenam | 1979 |
[Current status of vascular diseases and their treatment].
Topics: Arteriosclerosis; Aspirin; Clofibrate; Humans; Indomethacin; Sulfinpyrazone; Vasodilator Agents | 1979 |
Dietary prevention of atherosclerosis: new aspects.
Topics: Animals; Arteriosclerosis; Aspirin; Cholesterol, Dietary; Diabetes Mellitus; Diet; Heart; Hypertensi | 1979 |
Inhibitors of platelet function and atherogenesis.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Dipyridamole; Disease Models, Animal; Humans; P | 1979 |
[Platelet aggregation in atherosclerotic disease after administration of lysine acetylsalicylate].
Topics: Adult; Aged; Angina Pectoris; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Coronary Disea | 1978 |
[Effect of acetylsalicylic acid and indomethacin on lipid metabolism].
Topics: Adolescent; Adult; Aged; Arteriosclerosis; Arthritis, Rheumatoid; Aspirin; Female; Humans; Indometha | 1978 |
[Correction of disorders of rheologic properties of blood in reconstructive operations on the abdominal aorta].
Topics: Adult; Aged; Aorta, Abdominal; Aortic Diseases; Arteriosclerosis; Aspirin; Blood Viscosity; Dipyrida | 1978 |
Antithrombotic therapy. Rationale and application.
Topics: Anticoagulants; Arteries; Arteriosclerosis; Aspirin; Blood Coagulation; Blood Coagulation Factors; D | 1979 |
[The effect of acetylsalicylic acid, extremely restricted movement and a cholesterol-rich diet on atheromatosis of the rabbit aorta: comparative investigations (author's transl)].
Topics: Animals; Aorta; Arteriosclerosis; Aspirin; Diet, Atherogenic; Immobilization; Male; Platelet Adhesiv | 1975 |
Platelets, thrombosis and atherosclerosis.
Topics: Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Cell Survival; Dipyridamole; En | 1977 |
Platelets, thrombosis and atherosclerosis.
Topics: Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Cell Survival; Dipyridamole; En | 1977 |
Platelets, thrombosis and atherosclerosis.
Topics: Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Cell Survival; Dipyridamole; En | 1977 |
Platelets, thrombosis and atherosclerosis.
Topics: Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Cell Survival; Dipyridamole; En | 1977 |
Observations with istopirine in the treatment of vascular complications.
Topics: Aged; Arteriosclerosis; Aspirin; Embolism; Female; Humans; Male; Middle Aged; Vascular Diseases | 1976 |
[Problems of arteriosclerosis epidemiology. Analysis of risk factors with a view to a possible therapy].
Topics: Anti-Inflammatory Agents; Anticoagulants; Antihypertensive Agents; Arteriosclerosis; Aspirin; Blood | 1976 |
Study on fibrinolytic activity induced by aspirin ingestion in patients with atherosclerosis.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Female; Fibrinolysis; Humans; Male; Middle Aged | 1975 |
Study of drugs affecting cholesterol-induced atherosclerosis in rabbits.
Topics: Animals; Arteriosclerosis; Aspirin; Chloroquine; Cholesterol, Dietary; Clomipramine; Hydroxyurea; Ma | 1976 |
Concomitant aspirin treatment abolishes the antiatherosclerotic effects of the calcium channel blocker isradipine mediated by PGI2.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Aspirin; Calcium Channel Blockers; Cholesterol; Dihydro | 1992 |
Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Atrial Fibrillation; Carotid Artery Diseases; Cerebral Infar | 1992 |
Evaluation of the clinical utility of platelet aggregation studies in the long-term follow-up of patients with atherosclerotic vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Dose-Response Relationship, Drug; Female; | 1992 |
The effect of antiplatelet therapy on platelet accumulation after experimental angioplasty in the rabbit iliac model.
Topics: Angioplasty, Balloon; Animals; Arteriosclerosis; Aspirin; Dipyridamole; Disease Models, Animal; Drug | 1992 |
Forum offers hints of future therapy, prevention programs for combating cardiovascular problems.
Topics: Animals; Arteriosclerosis; Aspirin; Cardiomegaly; Cardiovascular Diseases; Female; Genetic Therapy; | 1992 |
The diminished extracellular matrix production induced by isradipine, a calcium channel blocker, is completely abolished by cyclooxygenase inhibition.
Topics: Animals; Arteriosclerosis; Aspirin; Calcium Channel Blockers; Collagen; Cyclooxygenase Inhibitors; D | 1992 |
[What is the minimal daily acetylsalicylic acid for prevention of vascular diseases and how is it best administered?].
Topics: Arteriosclerosis; Aspirin; Humans | 1992 |
Cardiovascular disease.
Topics: Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Female; Humans; | 1992 |
Effects of laser-generated tissue debris on aggregation of human platelets.
Topics: Aged; Angioplasty, Laser; Animals; Aorta; Aortic Diseases; Arteriosclerosis; Aspirin; Blood Coagulat | 1991 |
[Duplex procedure in prevention of arteriosclerosis].
Topics: Adult; Arteriosclerosis; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Humans; Hypolipid | 1991 |
Effect of aspirin on intimal hyperplasia and cholesterol uptake in experimental bypass grafts.
Topics: Animals; Arteriosclerosis; Aspirin; Cell Division; Cholesterol; Dogs; Graft Occlusion, Vascular; Hyp | 1991 |
[Early detection and modification of preclinical arteriosclerosis].
Topics: Anticholesteremic Agents; Arteriosclerosis; Aspirin; Dipyridamole; Drug Therapy, Combination; Endoth | 1990 |
A biological method for studying the interaction between platelets and vascular endothelium.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Aspirin; Blood Platelets; Endothelium, Vascular; Epopros | 1990 |
Differential inhibition of thromboxane A2 and prostacyclin synthesis by low dose acetylsalicylic acid in atherosclerotic patients.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Cyclooxygenase Inhibitors; Epoprostenol; Female; | 1990 |
Platelet scintigraphy and survival in juvenile stroke patients.
Topics: Adult; Arteriosclerosis; Aspirin; Blood Platelets; Carotid Arteries; Carotid Artery Diseases; Cell S | 1990 |
[Changes of adrenoceptor density in heart and brain and the reactivity of isolated pulmonary artery ring in atherosclerotic rabbit].
Topics: Animals; Arteriosclerosis; Aspirin; Brain; In Vitro Techniques; Male; Muscle Contraction; Muscle, Sm | 1990 |
Patterns of failure of aspirin treatment in symptomatic atherosclerotic carotid artery disease.
Topics: Aged; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Cerebral Infarction; Humans; Middle Aged; | 1990 |
Human equivalent doses of platelet inhibitors and experimental atherosclerosis.
Topics: Animals; Aorta; Arteriosclerosis; Aspirin; Blood Platelets; Dipyridamole; Dose-Response Relationship | 1990 |
[Determination of human sensitivity to the antiaggregation action of acetylsalicylic acid].
Topics: Arteriosclerosis; Aspirin; Diabetes Mellitus; Humans; Methods; Myocardial Infarction; Platelet Aggre | 1986 |
Endothelium in the pathogenesis of main vascular diseases.
Topics: Animals; Arteriosclerosis; Aspirin; Cholic Acid; Cholic Acids; Endothelium, Vascular; Heparin; Homoc | 1989 |
[Influencing the fibrinolytic activity by antithrombotics in patients with atherosclerosis].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Blood Coagulation Tests; Fibrinolysis; Humans; Platelet F | 1989 |
Thromboxane A2 and prostacyclin generation in the microvasculature of patients with atherosclerosis--effect of low-dose aspirin.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Arteriosclerosis; Aspirin; Bleeding Time; Blood Platelets; Drug | 1989 |
Spontaneous atherosclerotic lesions and prostacyclin formation in rabbits: effects of combined dipyridamole and aspirin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Arteries; Arteriosclerosis; Aspirin; Dipyridamole; Dru | 1989 |
[The relationship between high-density lipoproteins, thromboxane B2 and arteriosclerosis in a case of primary hypoalphalipoproteinemia].
Topics: Adult; Arteriosclerosis; Aspirin; Chronic Disease; Histiocytes; Humans; Hypolipoproteinemias; Lipopr | 1989 |
Individually controlled aspirin in the long-term treatment of patients with chronic arterial diseases.
Topics: Adenosine Diphosphate; Arteriosclerosis; Aspirin; Blood Platelets; Brain Ischemia; Coronary Disease; | 1989 |
[Laboratory diagnostic monitoring of individually dosed antithrombotic therapy with acetylsalicylic acid in patients with atherosclerosis].
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Humans; Malonates; Mal | 1989 |
Mechanisms responsible for inhibition of vein-graft arteriosclerosis by fish oil.
Topics: Animals; Arteriosclerosis; Aspirin; Carotid Arteries; Dogs; Drug Evaluation, Preclinical; Drug Thera | 1989 |
Analysis of risk factors for myocardial infarction following carotid endarterectomy.
Topics: Arteriosclerosis; Aspirin; Carotid Artery Diseases; Coronary Disease; Endarterectomy; Female; Humans | 1989 |
Blood lipid peroxides in TIA: relation to platelet function and metabolic profile.
Topics: Administration, Oral; Aged; Arteriosclerosis; Aspirin; Blood Glucose; Blood Platelets; Coronary Dise | 1989 |
Model system to study interaction of platelets with damaged arterial wall. II. Inhibition of smooth muscle cell proliferation by dipyridamole and AH-P719.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arteries; Arteriosclerosis; Aspirin; Blood Platelets; | 1988 |
Indium-111-labeled platelet scintigraphy in carotid atherosclerosis.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Blood Platelets; Carotid Artery Diseases; | 1989 |
Platelet deposition at angioplasty sites and platelet survival time after PTA in iliac and femoral arteries: investigations with indium-111-oxine labelled platelets in patients with ASA (1.0 g/day)-therapy.
Topics: Adult; Aged; Angioplasty, Balloon; Arteriosclerosis; Aspirin; beta-Thromboglobulin; Blood Platelets; | 1987 |
[Can the progression of arteriosclerosis be influenced pharmaco- logically?].
Topics: Adult; Aged; Aged, 80 and over; Arteries; Arteriosclerosis; Aspirin; Female; Follow-Up Studies; Fura | 1988 |
Plasma thromboxane and prostacyclin metabolite ratio in atherosclerosis and diabetes mellitus.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Arteriosclerosis; Aspirin; Diabetes Mellitus; Epoprostenol; Fem | 1987 |
Individually controlled acetylsalicyclic acid (ASA) in the long-term treatment of patients with arteriosclerosis.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine Diphosphate; Arteriosclerosis; Aspirin; Biomarkers; Humans; | 1988 |
Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men.
Topics: Adult; Age Factors; Arteriosclerosis; Aspirin; Epoprostenol; Humans; Male; Middle Aged; Prostaglandi | 1988 |
Effect of dietary lipids on arterial thrombus formation: rationale for the support of drug therapy by diet.
Topics: Animals; Arteriosclerosis; Aspirin; Diet, Atherogenic; Dietary Fats; Disease Models, Animal; Fish Oi | 1988 |
Platelet aggregation and atherosclerosis.
Topics: Arteriosclerosis; Aspirin; Dipyridamole; Electrocardiography; Humans; Male; Middle Aged; Myocardial | 1986 |
[Prevention and medical treatment of polyregional vascular lesions].
Topics: Adult; Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Diet; Dipyridamole; D | 1985 |
Drug effects on platelet deposition after endothelial injury of the rabbit aorta.
Topics: Animals; Aorta; Arteriosclerosis; Aspirin; Dipyridamole; Endothelium; Epoprostenol; Ibuprofen; Plate | 1985 |
[Activity of ticlopidine and lysine acetylsalicylate in experimental atheromatosis. Effects on the production of PGI2].
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Arteriosclerosis; Aspirin; Diet, Atherogenic; Epoprost | 1985 |
The effects on lipids, blood viscosity and platelet aggregation of combined use of niceritrol (Perycit) and a low dose of acetylsalicylic acid.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Blood Viscosity; Diabetes Mellitus; Female; Fibrinogen; Huma | 1985 |
The influence of antiplatelet drugs on injury-stimulated migration of cultured smooth muscle cells.
Topics: Animals; Arteriosclerosis; Aspirin; Catheterization; Cell Movement; Cells, Cultured; Dipyridamole; H | 1985 |
Treatment of atherosclerosis and thrombosis with aspirin.
Topics: Adult; Age Factors; Animals; Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Diabetes | 1972 |
Letter: Heparin thrombin clotting-time and platelet factor 4.
Topics: Adult; Arteriosclerosis; Aspirin; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Te | 1974 |
[Collagen and thrombocytes].
Topics: Aorta; Arteriosclerosis; Aspirin; Blood Platelets; Collagen; Hemorrhage; Humans; Phenylbutazone; Pla | 1969 |
[Some problems of drug treatment in old age].
Topics: Age Factors; Aged; Androgens; Anti-Bacterial Agents; Arteriosclerosis; Aspirin; Cardiac Glycosides; | 1974 |
[Renewal of platelets and duration of inhibition of the second aggregation wave after a single dose of aspirin].
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cell Aggregation; Cell Survival; Humans; In Vitro Techni | 1972 |
Protection against epinephrine-induced myocardial necrosis by drugs that inhibit platelet aggregation.
Topics: Animals; Arteriosclerosis; Aspirin; Catecholamines; Dipyridamole; Dogs; Epinephrine; Heart; Myocardi | 1972 |
Chronic intravascular coagulation syndrome associated with atherosclerotic aortic aneurysm.
Topics: Aged; Aortic Aneurysm; Arteriosclerosis; Aspirin; Blood Cell Count; Blood Platelets; Chronic Disease | 1973 |
Editorial: Aspirin and atherosclerosis.
Topics: Arteriosclerosis; Aspirin; Depression, Chemical; Humans; Myocardial Infarction; Platelet Adhesivenes | 1974 |
[Role of thrombotic agent in coronary insufficiency--therapeutic implications (author's transl)].
Topics: Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelet Disorders; Coronary Disease; | 1974 |
Arterial and venous thromboembolism: kinetic characterization and evaluation of therapy.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Blood Cell Count; Blood Platelets; Dipyridamole; Drug Synerg | 1974 |
[Abnormalities of platelet aggregation during essential thrombocythemia. Effect of aspirin on erythromelalgia].
Topics: Adenosine Diphosphate; Aged; Arteriosclerosis; Aspirin; Blood Cell Count; Blood Platelet Disorders; | 1972 |
[Pathologic and therapeutic similarities between arteriosclerosis and lithiasic cholecystitis].
Topics: Acetamides; Aminosalicylic Acids; Animals; Arteriosclerosis; Aspirin; Cholecystitis; Cholelithiasis; | 1971 |